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Abstract 
Ru(II) half-sandwich "piano-stool" complexes [(i6-arene)Ru(en)Cl] (en = 
ethylenediamine), such as ftq6-bip)Ru(en)Clf (hip = biphenyl) and 
[(6  
tha)Ru(en)Cl] (tha = tetrahydroanthracene), show anticancer activity both in vitro 
and in vivo via hydrolysis, including activity against ciplatin-resistant cell lines. 
However, potential physiological and medical applications of these Ru(II) arene 
anticancer complexes are impeded by a lack of knowledge of competition between S-
donor peptides/proteins by which cisplatin is deactivated and N-donor nucleotides 
for these Ru(II) complexes. 
It is reported here that the Ru(II) arene anticancer complex [(11 	binds 
strongly to guanine (as cGMP and 14-mer DNA oligonucleotides) under 
physiologically-relevant conditions (micromolar concentrations, pH 7, 22 mM NaCl, 
310 K), even in the presence of a 250-fold molar excess of glutathione (GSH). 
Reactions between the Ru(II) complex and GSH carried out in water without 
buffering follow a different course: a tri-glutathione-bridged dinuclear Ru(II) 
complex [((r 6-bip)Ru)2(GS)3] is the final product, and three intermediates [(TI 
6_  
bip)Ru(en)(GS)] (same formula but different binding sites) are obtained as well; 
whereas in reactions of the Ru(II) complex with GSH in phosphate buffer (pH 7), 
only a mono-ruthenium-glutathione complex [(r16-bip)Ru(en)(GS)] was obtained, the 
same as one intermediate in the same reaction carried out in aqueous solution without 
buffering. In the presence of air, this thiolate [(ij 	is susceptible to 
oxidation, forming the sulfenate [(ij 	which protonates to the 
unstable sulfenic acid [(71 	that can be readily substituted by 
guanine bases (as cGMP and 14-mer DNA oligonucleotides in this thesis); whereas 
a dinuclear Ru(0) complex { [(TI 	(p.-S-GSO)2[(GS02)Ru(0)(r6- 
bip)]}9 is observed when bubbling with Ar, and it probably plays a similar role to 
{( 6-bip)Ru(en)(G(0)S)] described above. 




 (hmb = hexamethylbenzene; Ph = 
phenyl) was reported to be cytotoxic to cancer cells (IC50 = 23 jiM, A2780 cells) but 
cannot hydrolyse to form the active aqua species. It is demonstrated here that GSH 




 to the sulfenato adduct [(i 
6_ 
 hrnb)RL1(en)(S(0)-iPr)] - m )Ru )(S(0)-/Pr)I , which is a key 
+ 
intermediate in the formation of cGMP adduct [(ii  -hmb)Ru(en)(cGMP-N7)] . The 





 which readily hydrolyses and binds to cGMP. 
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This thesis is concerned with investigations into the mechanism of cytotoxic action 
of ruthenium(II) arene complexes. In this Chapter an introduction to inorganic 
anticancer complexes is given, particularly focusing on ruthenium(II) arene 
complexes, and oxidation of thiols. The aims of this thesis are also described. 
1.1 Metals in Life 
The first metal (from Greek 'Metallon') discovered on Earth was gold in 6000 BC 
due to Process Metallurgy which is one of the oldest applied sciences.thl  Metals at 
low levels in human body fluids and tissues (nanograms or micrograms per gram or 
per millilitre) are called trace elements which are composed of essential and non-
essential elements, and in the absence of an essential element, such as chromium, 
cobalt, copper, iron, manganese, molybdenum, nickel, selenium, tin, vanadium and 
zinc, a deficiency syndrome developsJ21 Transition metal ions are present in living 
organisms mainly bound to the usual donor atoms: N, 0 and S which are present in 
proteins in their amino acid residues. 31 The first-transition-series elements Zn, Cu, 
Mn, Fe and Co are found in metallo-enzymes in the human body. 31  
1.2 Inorganic Drugs Used in Cancer Therapy 
Cancer is a group of diseases in which cells are aggressive (grow and divide without 
respect to normal limits), invasive (invade and destroy adjacent tissues), and/or 
metastatic (spread to other locations in the body), which differentiate cancers from 
benign tumours. 41 Cancer can cause 13% of all deaths, 151  which is the second main 
cause of death in the western world. 61 Much more interest has been focused on 
research into metal-based anticancer drugs since the discovery of cisplatin [cis- 
2 
PtCl2(NH3)2] by Barnett Rosenberg in the 1960's. Pt, Ti, V, Mo and Ru have been 
used as metal centres in antitumour compounds. 791  
1.2.1 Platinum 
Several platinum anticancer complexes were synthesized since the anticancer activity 
of Cisplatin was discovered in the 1960s.[b01h1  Cisplatin is the most successful 
anticancer drug in the world, and is used to treat a wide range of cancers, including 
testicular, ovarian, cervical, bladder, and head and neck cancers. [12]  Cisplatin is 
administered to the blood stream, and hydrolysis is inhibited due to the relatively 
high chloride ion concentration in blood (ca. 100 mM). Upon entering the cell, the 
chloride concentration drops to ca. 20 mM, and cisplatin is hydrolysed to cis-[ 
PtCI(NH3)2(H20)1 + and cis-[ Pt(NH3)2(H20)2]2+  , which are more active forms of the 
drug. 3' These aqua species bind preferentially to the N7 position of guanine bases of 
DNA, which is the most electron rich site of DNA, to form 1 ,2-intrastrand adduct by 
binding at two neighbouring G-N7 basesJ'41 Cisplatin is considered to block 
replication and inhibit transcription by binding to DNA, leading to apoptosis of the 
cancer cell. 5' 
However, cisplatin has some serious drawbacks, including (1) severe toxicity such as 
nausea, ear damage, vomiting, loss of sensation in hands and kidney toxicity; (2) 
tumour resistanceJ'41 It is also only effective to a narrow range of cancers, which led 
to the development of new generations of platinum drugs (Figure 1.1). Furthermore, 
the high affinity between Pt(II) and sulfur-containing biological molecules, such as 
cysteine, methionine, glutathione and metal lothionein, is known. It is believed that 
the sites on proteins are the most likely origin of the toxic side effects of cisplatin 
and its several derivatives.116"71 Significant amounts of cisplatin are lost due to 
3 
binding to S atoms. To date over 3000 platinum complexes have been synthesised 
and tested for antitumour activity, 1181 but only a few of these have been made into 
clinical trials,1191 and there are only five other platinum drugs approved for clinical 
use (in at least one country)J201  
H3N\ /CI 	H3N\ 
H3N" Pt H3N" Pt 
 N0 0  
Cisplatin 	Carboplatin 




0 N / Pt( 
H2 	0 
Oxaliplatin 
Figure 1.1 The chemical structures of the platinum anticancer drug ciplatin and some 2' 
generation platinum drugs: carboplatin, nedaplatin and oxaliplatin. 
1.2.2 Ruthenium 
Both the success of cisplatin and its limitations have led to the search for other metal-
based anticancer drugs. Ruthenium along with Os, Rh, Ir, Pd and Pt, forms the 
platinum group metals. Ruthenium is a group 8 transition metal of the platinum 
group, and its oxidation states range from 0 to +8, though oxidation states of +2 and 
+3 are most common in aqueous solution. Approaches to the design of new active 
ruthenium complexes have rapidly evolved in recent years. Many ruthenium 
complexes increase the lifetime expectancy of tumour-bearing hosts due to their low 
cytotoxic potential in vivoJ21' However, they were still expected to reduce tumour 
growth by a mechanism of interaction with cellular DNA, similar to that of 
cisplatin. 211 At present, ruthenium is probably the second after platinum in the 
number of its complexes that exhibit anticancer activity. [221 
11  
1.2.2.1 Rutheium(III) Complexes 
Ruthenium(III) was considered as a promising candidate, 231 due to the similar 
spectrum of kinetic acitivity as platinum(II) 221 and its lower toxicity. In the 1970's, 
anticancer activity was reported for several ruthenium amine compounds by Clarke, 
particularly fac-{RuC13(NH3)3],1241 but it has very poor water solubility. Since this 
discovery, two ruthenium(III) compounds have entered clinical trials, trans-
[RuC14(DMSO)(Im)]ImH (NAMJ-A; Tm = imidazole) which is an antimetastatic 
complex, meaning that it is relatively inactive to primary tumours but prevents the 
spread of cancer from the primary site to other sites in the body, [251  and trans-[RuC14 
(Tnd)2]IndH (KP 1019; Ind = indazole) which is active against colorectal tumours, 1261 
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It has been suggested that ruthenium(III) anticancer complexes remain in their 
relatively inert Ru(III) oxidation state until they reach the tumour site, and reduce to 
the more reactive Ru(II) complexes due to its lower oxygen content and more acidic 
pH in tumours than those in normal tissue. 1211 Therefore, ruthenium(II) complexes 
were widely studied. 
1.2.2.2 Ruthenium(II) Arene Anticancer Complexes 
Based on the proposal that Ru(II) may be the active species of ruthenium(III) 
anticancer drugs, work in our group has turned to researches into Ru(II) anticancer 
complexes, especially these organometallic ruthenium(II) arene complexes with a 
"piano-stool" structure as shown in Figure 1.3(A). 
(C) 	
H3CCH3 	+ 




Figure 1.3 	(A) General chemical structure of Ru(II) arene complexes with "piano-stool" 
structure, {(i6-arene)Ru(X)(YZ)];  (B) Chemical structure of complex [(Tl  
(bip = biphenyl, en = ethylenediamine); 	(C) Chemical structure of complex [(ij 
hmb)Ru(en)(SPh)] (hmb = hexamethylbenzene). 
Ruthenium(II) arene complexes containing an arene like biphenyl (hip) or 
hexamethylbenzene (hmb), a chelating ligand (YZ) such as ethylenediamine (en), 
and a leaving group (X) such as halide (Cl, Br and I) or thiolate SR (R = Ph, 
isopropyl), Figure 1.3(B) and (C), have been reported to be cytotoxic to cancer 
cells. [27-311 
rel 
1.2.2.2.1 Mode of Action 
The mechanism of cytotoxic action of Ru(II) arene complexes, e.g. 
bip)Ru(en)Cl], is generally thought that the intact chioro complex is a "pro-drug" 
which is activated in vivo by hydrolysis of the Ru-Cl bond, and it is inhibited in the 
blood where high chloride concentrations are present (ca. 100 mM), while in the cell 
(4-25 mM [CI-]) the chloro complex is mainly hydrolysed to form the reactive 
species [(ij 	The aqua form then selectively binds to the N7 
position of guanine (G) bases in DNA (Scheme 1.l)J3334' 
Scheme 1.1 Mechanism of cytotoxic action of Ru(lI) arene complexes. 
R\ fl+ 
I 	2 
X1U %4 1 	hydrolysis  
"Pro-drug" 







Interestingly, one novel ruthenium(II) arene complex [(16-hmb)Ru(en)(SPh)] 
(Figure 1.3(C)) was found to have anticancer activity but no hydrolysis was 
observed. 311 The mechanism of cytotoxic action of this complex was proposed to 
involve the oxidation of sulphur (discussed in Chapter 5). 
Ruthenium(II) arene complexes [(ij 	were found to be active 
against cisplatin-resistant cell lines. l351  Their binding to DNA can only give rise to 
monofuctional adducts compared to the bifunctional adducts of cisplatin, and DNA 
7 
was more difficult to repair after treated with [(il 	than that treated 
with cisplatin. 36'371  
1.2.2.2.2 Rote of Coordinated Arene 
The arene group appears to play a major role in the anticancer activity of complexes, 
which is considered as a 2t-acid I it-acceptor ligand towards Ru(II). The IC50 values 
(the dose which inhibits growth of 50% of the cells) decrease (increase in activity) 
with increase in hydrophobicity of arenes (see Figure 1.4 and Table 1.1)J35' 
Arene = 
Arene + KII >-ç--- 0-0 








dihydroanthracene 	 tetrahydroanthracene 
(dha) 	 (tha) 
Figure 1.4 Ruthenium(II) arene complexes with different arenes. 
Table 1.1 	IC50 values against human ovarian A2780 cancer cells after 24 h complex 
exposure. 35' 
The arene can stabilise ruthenium in its +2 oxidation state, as well as makes the 
whole molecule hydrophobic which may assist in crossing cell membranes. The 
reason for the increase in activity with increase in hydrophobicity of arenes is that 
the extended arenes can intercalate into DNA to form strong intramolecular ir—ic 
arene-nucleobase stacking, [34'361  which is supported by the X-ray crystal structures of 
















Figure 1.5 it-it 
arene-nucleobase stacking. (A) X-ray crystal structure of [(16 
dha)Ru(en)(9EtG-N7)]2 
 (B) Chemical structure of 9-ethyguanifle (9EtG); (C) Model of 
the ruthenium(H) arene complex binding to B-DNA, showing how the  coordinated arene can 
insert between G base pairs. Figure reproduced from reference 38. 
The rate of reaction with cyclic guanosine monophophate (cGMP) increases with the 
increase in hydrophobicity of arenes due to the it-it arene-nucleobase stacking (Table 
I 
Table 1.2 Half lives 411) for reactions of [(q6  -arene)Ru(en)ClJ (2 mM) with cGMP (Ru:G 
= 1:1) containing 100 mM NaC104 at 298 K.1391 
Arene 	 t 12 / h 
tha 	 1.! 
bip 	 2.0 
dha 	 3.6 
p-cym 	 7.1 
bz 	 13 
1.2.2.2.3 Chelating Ligand (YZ) 
The chelating ligand, which increase the thermodynamic stability of the complex due 
to the chelate effect, showed significant effect on the reactivity of Ru(II) arene 
complexes. It was found that monodentate ligands on Ru(II) arene complexes are 
more labile than bidentate ligands, and Ru(II) arene complexes with monodentate 
ligands, like [(ij 	and [(q6-p-cym)Ru(isonicotinamide)2C l], 
are inactive against human ovarian A2780 cancer cells. r291 Ethylenediamine (en) is 
mostly used as the chelating ligand in Ru(II) arene anticancer complexes. 
1.2.2.2.4 Leaving Group (X) 
Hydrolysis of the Ru-X bond is believed to be correlated with the cytotoxicity of 
Ru(II) arene complexes because the aqua adduct [(Tl 	is the 
reactive species to biological molecules. The correlations between hydrolysis rates 
and cytotoxicity have been investigated for the Ru(II) complexes [(11 
hmb)Ru(en)Xf', in which high activity is for complexes that aquate readily, e.g. X = 
halide, whereas inactivity for those that do not aquate, e.g. X = pyridine (see Figure 
1311 	 + 1.6). An exception to this rule is the complex (T1 6 hmb)Ru(en)(SPh)] , which is 
active against human ovarian A2780 cancer cells (1050 = 23 1tM) although it is 
relatively inert to hydrolysis. 
13 11 It is proposed that it follows different mechanism of 
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Figure 1.6 Correlation of hydrolysis with cytotoxicity. (A) Chemical structures of RU(11) 
arene complexes with different leaving groups; 	(B) Hydrolysis rates and equilibrium 
percentage of total Ru as [(l6 hmb)Ru(efl)(H2O)]2  (top); cytotoxicity (1050 
values) for [(if-




Glutathione (y-L-Glu-L-Cys-Gly, abbreviated GSH) is a tripeptide composed of 
glutamate acid, cysteine and glycine (Figure 1.7(A)), which is a potentially 
polydentate ligand, and is widely used as a model system for the binding of metal 
ions by peptides and proteins. It is an abundant (millimolar) intracellular thiol 
responsible for the deactivation of heavier transition metal ions, including some 
platinum and ruthenium anticancer complexes. 40 	Glutathione is present in several 
additional forms in cells, tissues and plasma, such as glutathione disulfide (GSSG; 
Figure 1.7(B)) which is one of the oxidation forms from GSH, sulfonates which are 






PKa2 	Glutathione (GSH) 
0 	 NH2 
'I H 
HOy)5 NyyOH  0 	 0 	0 
0 	0 	 0 
HO N N OH  
NH2 	 0 
Glutathione disulfide (GSSG) 
Figure 1.7 Chemical structures of GSH (A) and GSSG (B). PKai = 2.19, PKa7 = 9.67, PKa3  
= 
13 
GSH is synthesized from L-glutamate, L-cysteine and glycine in two steps, catalyzed 
by -y-glutamyl-cysteine synthase and glutathione synthase, requiring two moles of 
ATP as shown in Scheme 1 .2J44' 










Glutathione has numerous important functions within cells. It serves as a reductant 
and is conjugated to drugs to make them more water soluble. It is also involved in 
amino acid transport across cell membranes (the y-glutamyl cycle) and is a part of 
the peptidoleukotrienes, and serves as a cofactor for some enzymatic reactions and as 
an aid in the rearrangement of protein disulfide bonds. [42] 
The role of GSH as a reductant is extremely important particularly in the highly 
oxidizing environment of the erythrocyte, in which the suithydryl of GSH can reduce 
peroxides forming during oxygen transport and the resulting oxidized form of GSH 
14 
consists of two molecules disulfide bonded together (GSSG, structure shown in 
Figure 1.7(B)). 1421   The enzyme glutathione reductase utilizes NADPH as a cofactor to 
reduce GSSG back to two moles of GSH. Several mechanisms exist for the transport 
of amino acids across cell membranes. Many are symport or antiport mechanisms 
that couple amino acid transport to sodium transport. The -glutamyl cycle is an 
example of a group transfer mechanism of amino acid transport. Although this 
mechanism requires more energy input, it is rapid and has a high capacity. The cycle 
functions primarily in the kidney, particularly renal epithelial cells. 1421 The enzyme y-
glutamyl transpeptidase is located in the cell membrane and shuttles GSH to the cell 
surface to interact with an amino acid. Reaction with an amino acid liberates 
cysteinyiglycine and generates a y-glutamyl-amino acid which is transported into the 
cell and hydrolyzed to release the amino acid. 1421  Glutamate is released as 5-
oxoproline and the cysteinylglycine is cleaved to its component amino acids. 
Regeneration of GSH requires an ATP-dependent conversion of 5-oxoproline to 
glutamate and then the 2 additional moles of ATP that are required during the normal 
generation of GSH. 1421 
1.4 Thiols and Their Oxidation Adducts 
Sulfur complexes are widely present in nature. Sulfur-containing substances play 
important biological roles. 
1.4.1 Oxidation of Thiols 
Thiol (RSFI) is one of the most reactive functional groups in cells, and biologically, 
the most important reactions of thiols are their oxidations to disulfides and higher 
15 
sulphur oxides, and in all these reactions sulfenic acids (RSOH) are involved. The 
pathways are shown in Scheme 1.3 [45461  




thiol 	 sulfenic acid 
RS02H 	 RS03H 
sulfinic acid sulfonic acid 
1.4.2 Sulfenic Acids 
Sulfenic acids are transient intermediates during the oxidation of thiols with mild 
oxidants such as a stoichiometric quantity of hydrogen peroxide (1-1202). They are 
recognised to be important intermediates in many organic reactions such as 
hydrolysis of sulfenyl halides, 147,481  decomposition of alkyl sulfoxides and 
thiosulfinates,149'50' autoxidation of thiols, 511  etc. Sulfenic acids were discovered in 
the 1940's and found to play an important role in reactions of extracts of Allium 
plants. 521  Three thiolato complexes RS(0)CH2CH(NH2)COOH (R = methyl, propyl 
and 2-propenyl) were detected in A ilium sativum L (garlic), and alliinase was 
induced to cleave the S-C bond, leading to the corresponding sulfenic acids RSOH 
which quickly condensed and gave the relatively stable thiosulfinic-S esters 
(thiosulfinates) RS(0)SR as shown in Scheme 1.4. [531 
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Scheme 1.4 Formation of sulfenic acids in AlIiun sativum (garlic). 
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Sulfenic acids are generally very unstable and highly reactive. They can act as either 
nucleophile (binding to transition metals) [14-11]  or an electrophile (attacked by another 
sulfenic acid) 531 under different reaction conditions. The main reason for their 
instability is the facile self-condensation reaction to form the corresponding 
thiosulfinates RS(0)SR as shown in Scheme 1.4. 1531  Two possible tautomeric 
structures have been considered for sulfenic acids in Scheme 1.5 E511. 





Sulfenic acids are generally thought to be stabilised either by steric inhibition or by 
formation of intramolecular hydrogen bonding between the sulfenic acid moiety and 
a suitable hydrogen bond acceptor. 591 The observation of hydrogen-bonded sulfenic 
acids in the reaction of sulfenic acid self-condensation, (601  and the intermolecular 
hydrogen bonding is believed to be particularly effective in lowering the potential 
energy or enthalpy of the reaction shown in Scheme 1.6.1591  However, Weigand et al. 
focused on stabilising anions of sulfenic acids by transition metal complexes to form 
sulfenates.158' The first report of a metal-sulfenato complex was published by George 
et al., in which the iridium compound IrCl2[S(0)CH3](CO)(PR3)2 was prepared.1611 
Then the controlled monooxidation of thiolates coordinated to cobalt(III) to Co-
coordinated sulfenates was reported. 162 '631 Transition metal fragments in lower 
oxidation states exhibit excellent it-donor ability, so the mesomeric structure VI 
shown in Scheme 1.7 has to be taken into account. 1581 
Scheme 1.6 Formation of intermolecular hydrogen bonding in the conversion of sulfenic 
acids to thiosulfinates.1591 
H\ .H\ 
o• 0 	 0 
I 	I II 
2 RSOH 	jP R-S S-R 	 RS-SR + H20 
Scheme 1.7 Metal-coordinated sulfenate and its mesomeric structure. t581  
0 	 O 
II 1 
LM-S-R 	 LM-S-R 
VI 
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1.4.3 Cys-SOH in Proteins 
In contrast, oxidation of cysteinyl side chains in proteins can be controlled to form 
cysteine-sulfenic acid (Cys-SOH) instead of forming a disulfide bond. The reactivity-
control of Cys-SOH has been shown to yield stable active-site Cys-SOH derivatives 
of papain and glyceraldehydes-3-phophate dehydrogenasej461 Cys-SOH stabilisation 
requires the absence of other sulfhydryl groups in the vicinity, furthermore, limited 
solvent access and association with apolar elements of protein structure should 
contribute to this stabilisationJ641 Although protein disulfides play an important role 
in the protein folding process, formation of protein disulfides can inactivate the 
activity of proteins due to the disappearance of the active-site Cys-SH in proteins. 
Therefore, oxidation of Cys-SH to Cys-SOH were used to protect the active-sites in 
proteins sometimesJ641 Recently, Cys-SOH has been found to be involved in redox 
catalysis, [65-67]  redox regulation [61-11]  (see Scheme 1.7) and redox signalling. 71 1 Also 
in the iron-containing nitrile hydratase (NHase), two Cys residues coordinated to the 
iron were found to be post-translationally modified to Cys-SOH and Cys-S02H, 721  
and NHase was irreversibly inactivated by the oxidation of Cys-SOH to Cys-
S02HJ73' 
Scheme 1.7 Diverse roles for Cys-SOH in redox catalysis and redox regulation. R is H, 





Cys-SH 	 Cys-SS-Cys 
Redox catalysis 	Redox catalysis 
(Npx, Nox, hORF6) Redox regulation 
Cys-SH 
Redox regulation 
(AP-1, E2, PTP's) 
(AhpC, HBP23, OxyR) 
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1.5 Aims 
The overall aim of this thesis is to investigate the mechanisms of the cytotoxic action 
of ruthenium(II) arene complexes. As illustrated in section 1.2.1, significant amounts 
of cisplatin are lost due to binding to S atoms, and some work in our group focusing 
on investigations of reactions of Ru(II) arene complexes with either cysteine, 
histidine, or 14-mer DNA oligonucleotides was carried out. This thesis is concerned 
with the competitive reactions of N-donor (G N7-DNA) and S-donor (GSH) ligands 
with Ru(II) arene anticancer complexes. More specific aims are shown as follows. 
Investigations of the reactions of {( 6-bip)Ru(en)Clf with GSH both in 
unbuffered water (pH ca. 3) and in phosphate buffer (pH 7). 
Studies of the mechanism for the competitive reaction of [(ij  
with GSH and cGMP at pH 7. 
Investigation of possible reactions of [( 6-bip)Ru(en)C1f with thiol-containing 
protein glutathione S-transferase (GST) at ca. pH 7. 
Investigation of the competition between GSH and 14-mer DNA 
oligonucleotides for ftq6-arene)Ru(en)Cl]. 
Studies of the mechanism of reaction of the cytotoxic Ru(II) arene thiolate 
6 	 + complexes ftri  -hmb)Ru(en)(SR)] 
FA 
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This Chapter involves the main experimental techniques used in the work shown in 
this thesis. More specific methods relating to particular experiments are outlined in 
the appropriate chapters. 
2.1 Ultraviolet-visible (UV-Vis) Spectroscopy 
Ultraviolet and visible absorption spectra were recorded on UV-Vis 
spectrophotometer (Perkin Elmer Company) which is connected with a temperature 
controller (in the range of 200-600 nm, using a 10 mm path length quartz cuvette at 
310 K. Spectra were processed with WinUV software. 
2.2 High Performance Liquid Chromatography 
(HPLC) 1,21 
A Hewlett-Packard series 1100 quaternary pump and a Rheodyne sample injector 
with 100 ,uL and 2.0-mL loops, a HP 1100 series UV-vis detector and HP 1100 series 
Chemstation with a HP enhanced integrator were used. 
2.2.1 Reverse Phase HPLC (RP-HPLC) 
RP-HPLC is the only type of HPLC used in this thesis. RP-HPLC consists of a non-
polar stationary phase (a spherical, rigid, macroporous polystyrene/divinylbenzene 
polymer packed in the PLPR-s column used in my work), and a moderately polar 
mobile phase (specific combinations of water and acetonitrile in this thesis). 
Therefore, the retention time is longer for non-polar molecules and shorter for polar 
27 
ones, which is also increased by the addition of polar mobile phase and decrease by 
the addition of more hydrophobic mobile phase. 
RP-HPLC separates components on the basis of principle of hydrophobic 
interactions. The binding strength of the component to the stationary phase is 
proportional to the contact surface area around the non-polar segment of the 
component molecule upon association with the ligand in the aqueous eluent. The 
retention time can be shortened by increasing less-polar solvent like acetonetrile into 
the mobile phase to reduce the surface tension of water. Also structural properties of 
the component molecule are related to its retention characteristics. Generally, the 
retention time for a molecule with a larger hydrophobic surface area, such as C-H, C-
C and generally non-polar atomic bonds (S-S), is increased due to the increase of the 
molecule's non-polar surface area which is non-interacting with water. In contrast, 
polar groups, such as —OH, —NH2, COO— and —NH3 , result in shorter retention 
times as they are well integrated into water. 
2.3 ElectroSpray lonisation Mass Spectrometry (ESI-MS) 
Positive-ion electrospray ionization mass spectra were obtained with a Platform II 
mass spectrometer (Micromass, Manchester, U.K.). A Waters 2690 HPLC system 
was interfaced with the mass spectrometer, using the column and gradients as 
described in each main chapter for the analytical HPLC separation, with a flow rate 
of 1.0 mL mm ' and a splitting ratio of 1/5. The spray voltage was 3.50-3.68 kV, and 
the cone voltage, 20 V. The capillary temperature was 410 K with a 450 L h '  flow of 
nitrogen drying gas. The quadrupole analyzer, operated at a background pressure of 2 
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X 10 Torr, was scanned at 700-900 Da s - Data were collected and analyzed on a 
Mass Lynx (ver. 3.5) Windows NT PC data system using the Max Ent Electrospray 
software algorithm and calibrated versus an NaT calibration file. The mass accuracy 
of all measurements was within 0.1 m/z unit. 
2.4 Nuclear Magnetic Resonance (NMR) Spectroscopy 11,3,4,51  
NMR data were acquired using Bruker Avarice 600 MHz NMR spectrometers 




N) z-gradicnt cryo-prohe or room 
-. 	1 	13 	15 
temperature FXI (11. C, N) triple-axis x,y,z) gradient prohehead. 
One-dimensional (ID) H NMR data were acquired with eight transients into 32k 
data points over a frequency width of 9.0 kHz using either water presaturation or a 
double-pulsed field gradient spin-echo routine (DPFGSE) to eliminate the solvent 
[61 
resonance. 
Two-dimensional (21)) ['H,'H] DQFCOSY, TOCSY, and NOESY NMR data were 
acquired over a frequency width of 5.4 kHz in both F2 and F1  into 2k complex data 
points in F2 (acquisition time = 190 ms) with two transients for each of 2 x  512 ii 
increments in the QF (COSY) or the States -TPPI (TOCSY and NOESY) mode. A 
relaxation delay of 1.4 s between transients was used for all experiments. 2D 
NOESY NMR data were acquired with mixing times of 100 and 400 rns. and 2D 
TOCSY data with a spin-lock time of 60 ms. Water suppression for COSY was 
achieved using water presaturation. For TOCSY and NOESY experiments, the water 
resonance was suppressed by means of a DPFGSE routine after the final read pulse. 





courses of the reactions containing N-labelled Ru complexes were 
followed by NMR using a Bruker Avarice NMR spectrometer operating at 800 MHz. 
All data were acquired on samples equilibrated at 310 K. A triple resonance (TBI: 
'H '3  . C,X) probehead equipped with a triple-axis (x,y,z) gradient coil was used for 
data accumulation. 
'5 
ID H NMR spectra were acquired without N-decoupling over an 8 kHz frequency 
width for eight transients into 16k data points (acquisition time = 1.022 s) with a 
relaxation delay of 1.5 s between transients. 'H pulse calibration was carried out 
using a presaturation pulse sequence (zgpr). Subsequently, 'H NMR data were 
acquired either using a DPFGSE routine or its modified form in which composite 
inversion pulses were applied. 
[7j 
 Gradients were used to select for IH_LN  colerences 
and were simultaneously responsible for eliminating the water resonance. 
I 	iS 	 is 
2D { H, N] HSQC NMR data were acquired, with N-decoupling during the 
acquisition period, over an F2 frequency width of 8 kHz (acquisition time = 128 ms). 
Multiples of eight transients were accumulated for each of 128 t, increments over an 
F, frequency width of 80 ppm centered at -30 ppm relative to ' NH4Cl (reference. 0 
ppm). Phase-sensitive data were acquired in a sensitivity-improved manner using an 
echo-antiecho acquisition mode. 181 
2.4.1 Water Suppression 
Most of the experiments in this thesis were performed in aqueous solution (90% 
D20/10% H20), in which a large HOD peak is present and can be suppressed using 
either presaturation or 1 D Double Pulse Field Gradient Spin Echo (DPFGSE; also 
called Shaka water suppression). Presaturation involves saturating the required signal 
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(in this case residual water) by irradiating the frequency of the water signal in 
between pulse sequences, however, this saturation is also transferred to the functional 
groups such as OH and NH protons which readily exchange with the protons of 
water. DPFGSE uses pulse field gradient spin echoes in which the refocusing pulse is 
the sequence soft it(x)-hard t(-x).t61  
2.4.2 Two Dimensional Spectroscopy 
2.4.2.1 COrrelation and TOtal Correlation SpectroscopY (COSY and 
TOCSY) 
COSY is a two-dimensional homonuclear (like ['H,'H])-correlation NMR 
spectroscopy, in which the presence of an off-diagonal (or cross) peak normally 
indicates that the protons giving the connected resonances on the diagonal are 
geminally or vicinally coupled. 
TOCSY is a similar technique as COSY, but in TOCSY, cross peaks are detected 
between all f-coupled members within a spin system. Magnetization is transferred 
successively over up to 5 or 6 bonds as long as successive protons are coupled. The 
number of transfer steps can be adjusted by altering the mixing time and can be tuned 
from 1-2 steps up to 5-7 steps. 
2.4.2.2 Nuclear Overhauser Enhancement SpectroscopY (NOESY) 
When the cross peaks derive from magnetization transfer through dipolar relaxation, 
the 2D experiment is termed NOESY. In the case of the NOESY experiment, 
valuable information is provided about the distance (or space) between various 
protons within a molecule. The NOESY experiment can provide both structural and 
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conformational information, and in practice, cross peaks are unobservable when the 
proton-proton distance exceeds about 5 A. 
2.4.2.3 2D I'H, '5N] Heteronuclear Single Quantum Correlation (HSQC) 
Spectroscopy 
The HSQC experiment generates single quantum '5N coherence via an INEPT 
(Insensitive Nuclei Enhanced by Polarization Transfer), which evolves and then is 
transferred back to the proton frequency by a second INEPT sequence, this time in 
reverse. The HSQC spectrum is 2D with one axis for 'H and other for a 
heteronuclear (15N in this thesis), which does not contain 'H-'H coupling in the '5N 
dimension. A heteronucleus in NMR terminology is a nucleus other than proton. And 
the spectrum contains a peak for each unique proton attached to the 15  N being 
considered. If the chemical shift of a specific proton is known, the chemical shift of 
the coupled '5N can thus be determined. The HSQC experiment is also useful for 
detecting interactions with ligands. By comparing the HSQC of the free '5N-labelled 
Ru(II) arene compound, it is possible to find the changes in the chemical shifts of the 
peaks, which occur due to the binding of Ru(II) complex with other ligands. 
2.5 Inductively Coupled Plasma Optical Emission Spectroscopy 
(ICP-OES)11'2'91  
ICP-OES is a kind of emission spectroscopy in which plasma is used to produce 
excited atoms that emit electromagnetic radiation at a wavelength characteristic of a 
given element, and it is a very sensitive technique. The intensity of the emission 
represents the concentration of the element involved in the analyte. The principle of 
the technique is to excite the atoms into the higher-energy level, and atomic emission 
occurs when the atoms return to the ground state with the release of the additional 
energy, and the energy is detected as emission radiation which is characteristic to the 
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element emitting. This technique is used to determine the Ru or P concentrations. 
The analyte, if solid, is normally dissolved and then mixed with water before being 
fed into the plasma. Atoms in the plasma emit light (photons) with characteristic 
wavelengths for each element, and the light is recorded by one or more optical 
spectrometers and after calibrated against standards, it provides a quantitative 
analysis of the original analyte. 
2.6 pH Measurements 
pH measurements were made using a Corning 240 pH meter equipped with an 
Aldrich micro-combination electrode calibrated with Aldrich standard buffer 
solutions of pH 4. 7, and 10. For NMR samples prepared in 10% D20/90% 1-120, no 
correction has been applied for the effect of deuterium on the glass electrode and the 
meter reading was denoted as pH*. 
2.7 Determination of Extinction Coefficients 
HPLC fractions were collected from their corresponding reactions. After 
lyophilization, the residue from each fraction was dissolved in 5 mL deionized water 
for Ru determination by ICP-OES, using a Perkin-Elmer Optima 5300 DV Optical 
Emission Spectrometer equipped with an AS-93plus autosampler and WinLab32 for 
ICP program (version 3.0.0.0103). The apparent extinction coefficient at 254 nrn (r' 
254) for each species was calculated using eq 1. 
' 254= [peak area]254/[Ru] (pmol) 	 (1) 
33 
The relative extinction coefficient E 
R 
 254 for each species was calculated from eq 2: 
ER 254 = [' 2541)1'6' 2541 
	
(2) 
where [ 254]x and [e 254] represent the extinction coefficients of species x and Ru 
complex [(ij 	bip = biphenyl) or [(16-hmb)Ru(en)(SPh)]PF6 
(23; hmb = hexamethylbenzene). respectively. 
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Chapter 3 
Reactions of Ruthenium(II) 
Arene Anticancer Complex 
[(q6  -bip)Ru(en)CI]PF6 with 
Glutathione or Protein 
Mel 
3.1 Introduction 
Several ruthenium(III) am(m)ine complexes such as cis-[RuCl2(NH3)4]C! and Na[trans-
Ru(Im)2C14] exhibit anticancer activity, and are thought to be activated by reduction (to 
Ru'1) in vivo which facilitates DNA bindingJ" Recently it has been shown that members 
of the family of Ru"  arene complexes [(T16-arene)Ru(YZ)(X)][PF6],  where X is a halide 
and YZ is a chelating diamine, in which the presence of the arene greatly stabilizes Ru"  
compared to Ru" 21  are cytotoxic to cancer cells including cisplatin-resistant cell lines. [31 
For chioro (X) ethylenediamine (YZ; en) complexes, the cytotoxicity increases with the 
size of coordinated arene in the order: benzene < p-cymene < biphenyl < 
dihydroanthrancene < tetrahydroanthrancene. The activity of several of the complexes 
against human ovarian cancer cell line A2780 is at least comparable to that of 
carboplatin, and some approach that of cisplatin. Activity has also been demonstrated 
against human xenographs in vivo. 3  
Platinum(lI) has a high affinity for sulfur-containing biological molecules. [4]  Although 
we have demonstrated that both cysteine and methionine can form S-bound adducts with 
[( 6-bip)Ru(en)Cl][PF6](1; bip = biphenyl )'151  the reaction of 1 and the tripeptide 
glutathione (y-L-Glu-L-Cys-Gly; GSH), an abundant (millimolar) intracellular thiol 
responsible for the detoxification of heavier transition metal ions, including some 
platinum and ruthenium anticancer complexes, 11,,6]  is investigated for the first time. 
As a member of the second transition series, ruthenium has seven isotopes, making the 
mass isotopic pattern of ion peaks of ruthenium-containing compounds characteric, yet 
complicated. Mass spectra obtained using electrospray ionisation mass spectrometry 
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(ESI-MS) with quadrupole analyser allow unambiguous assignment of singly-charged 
ion peaks of mono-nuclear ruthenium arene complexes as well as their adducts with 
amino acids, peptides and DNA15'7101 However, low resolution Q-ESI-MS cannot 
identify two multi-nuclear ruthenium cluster arising from the reaction of the ruthenium 
arene anticancer complex [(rl 	(1; bip=biphenyl) with the tripeptide 
glutathione in aqueous solution. 71  
Glutathione transferases (GSTs) are a super-family of multi-functional isoenzymes 
involved in the detoxication of the cell against toxic and carcinogenic compounds, 
cellular mechanism of drug resistance, biosynthesis of leukotrienes, and intracellular 
binding and transport of hydrophobic ligandsJ' 11 A well known function of GSTs is to 
promote the conjugation of the sulphur atom of glutathione to an electrophilic centre of 
endogenous and exogenous toxic compounds, thereby increasing their solubility and 
excretionJ' 1]  The GSTs are potential drug targets in cancer therapy, where resistance to 
chemotherapeutic drugs has been directly correlated with the overexpression of GSTs in 
tumor cells, and parastic diseases such as malaria and schistosomiasisJ12' Cytosolic 
GSTs are dimeric, and two GST isoenzymes, of 26 and 28 kDa, are found in 
SchistosomajaponicumJ' 3  I The X-ray crystal structure of the 26 kDa GST (called 26-
kDa GST) from S. japonicumH 3l which was used for the work in this Chapter is shown in 
Figure 3. 1, in which four free thiol groups are present. 
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Figure 3.1 Crystal structure of Sj26GST monomer (PDB ID: lM99).E'31 Four cysteines with free thiol groups (Cys85, Cys138, Cys169 and Cys178) are labelled: yellow ball is S atom; red is 
0 atom; purple is N atom and grey is C atom. 
In this Chapter, the work is focused on reactions of the Ru11 anticancer complex 
bip)Ru(er)Cl][PFd(l) with GSH. In particular, reactions under physiologically relevant 
conditions: micromolar Ru concentrations, p1-I 7, and millimolar GSFI concentrations, 
were studied. Surprisingly S-bound glutathione was found to be susceptible to oxidation, 
and reactions carried out in water without buffering followed a different course. The 
findings suggest that novel redox reaction pathways could contribute to the biological 
activity of organometallic Ru
11  arene complexes. And high resolution Fourier transform 
ion cyclotron mass spectrometry (nanoLC-FT-ICR-MS) was applied to identify the 
clusters separated by nanoscale liquid chromatography as the dinuclear complex {[(
1 
16- 
bip)Ru(0)(GS02)2]2 18- and tetranuclear complex 	{[(TI 
6  -bip)Ru(II)(GS02)12[(Tj 
 6_ 
bip)Ru(l)(GS02)12 12 
(16-bi )( SO2)]2[( 6-
(I)(GSO2)]2}2 containing glutathione sulfenate and sulfinate ligands. Use of 
180H2 showed that the oxygen in the oxidized glutathione ligands arises from water. The 
reaction of 1 with GST at pH 8 was analyzed, and gave rise to a di-ruthenated GST 
adduct ([(116  -bip)Ru(en)12(GST)12+ 
3.2 Experimental 
3.2.1 Materials 
6 	 5 
[(ii -bip)RUCI(en)I[PF61(1) and N-labeled I ( N-i) were synthesized by Haimei Chen 
as described elsewhere. E34]  Glutathione (GSH, reduced), sodium chloride, disodium 
hydrogen phosphate, 5, 5' -dithio-bis-(2-nitrobenzoic acid) (3-carboxy-4-nitrophenyl 
disulfide; DTNB), and Chelex resin (used for removal of impurity ions from phosphates) 
were purchased from Sigma; sodium dihydrogen phosphate and the ruthenium standard 
for atomic spectrometry (1003 1igRu/mL ) from Aldrich; sodium hydroxide and sodium 
chloride from Fisher; and trifluoroacetic acid (TFAH) from Acros. 180-Iabled water 
(95% H2180) from Cambridge Isotope Laboratories. Untagged glutathione s-transferase 
(GST) in Tris buffer (pH 8) was synthesized and purified by Ms. Ann Marie Reid 
described elsewhere. [151 
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3.2.2 Methods 
3.2.2.1 High Performance Liquid Chromatography (HPLC) 
The instrument was outlined in Chapter 2.2. For analytical work, HPLC separations 
were carried out on a PLRP-S reversed-phase column (250 mm x  4.6 mm, 100 A. 5 pm. 
Polymer Labs) with detection at 254 rim. And semipreparative work on a PLRP-S 
reversed-phase column (250 mm x  7.5 mm, 100 A, 8 pm, Polymer Labs). Mobile phase 
A: water (for HPLC application, Fisher Chemicals) containing 0.1% TFAH; mobile 
phase B: acetonitrile (for lIPLC application. Fisher Chemicals) containing 0.1% TFAH. 
The flow rate was 1.0 rnL mm '. The gradient (solvent B) was as follows: 2% to 28% 
within 20 mm, 80% from 21 to 24 mm, reset to 2% from 26 to 30 mm. 
3.2.2.2 Nanoscale Liquid Chromatography Fourier Transform Ion 
Cyclotron Mass Spectrometry 
All the nano-LC-FT-ICR-MS experiments were operated by Mr. Stefan Weidt. Positive-
ion electrospray ionization mass spectra were obtained with a Bruker APEX III ESI-FT-
ICR mass spectrometer (Bruker Daltonics, USA) equiped with an inhouse modified 
heated metal transfer capillary held at a temperature of 423 K and a potential of 50V. A 
UltiMate 3000 series system (Diones, UK) with nanoflow splitter was coupled to the 
mass spectrometer using an TriVersaTM NanoMate® (Advion, USA) with spray voltage 
set to 1.7 W. Mobile phase A: water (for LC-MS application, Fisher Chemicals) 
containing 2% CH3CN and 0.1% TFAH; mobile phase B: acetonitrile (for LC-MS 
application, Fisher Chemicals) containing 20% water and 0.1% TFAH. The sample was 
trapped and washed for 3 min at 30 jiL min-] on a .t-PrecolumnTM (300 jtm x  5 mm, 5 
bOA). The sample was eluted onto an analytical PepMapTM 100 column (75 jim 
15 cm, 3 jim, bOA) held in a column-oven at 303 K. The flow rate was 300 nL min 1 , 
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and gradient (solvent B) was as follows: 0% to 30% until 23 mm, 30% to 100% from 23 
to 24 mm, 100% from 24 to 27 mm, 100% to 0% from 27 to 29 min and reset to 0% 
until 30 mm. All spectra were acquired using Wass 7.02 (Bruker Daltonics) with 512k 
datapoints in the range 90 to 3000 m/z. Bruker Daltonics Data Analysis software was 
used for analysis and postprocessing. 
3.2.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
For HPLC-isolated glutathione products, NMR data were acquired at a temperature of 
298 K. The methods were described in Chapter 2.4. 
All NMR data were processed using Xwin-nmr (version 3.5, Bruker Biospin. Ltd.). 
3.2.3 Preparation of Samples 
3.2.3.1 UV-Vis 
The method was described in Chapter 2.1. The UV-Vis spectra of reaction mixtures of 1 
and GST at various molar ratios in Tris buffer (pH 8) at 310 K were recorded every 5 
mm. The reaction mixture of I with GST (80:20 jiM) in Iris buffer (pH 8) at 310 K for 6 
h was analysed by FT-ICR MS after monitoring by UV-Vis spectroscopy. 
3.2.3.2 HPLC 
Reaction mixtures of complex 1 with GSH at various molar ratios were prepared by 
mixing aliquots of 10 mM 1 and 50-500 mM GSH. For the reactions under 
physiologically relevant conditions (phosphate buffer pH 7.0, 22 mM NaCl), the pH 
values of all starting solutions were adjusted to 7 using NaOH and HCI04, and the 02 
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content was minimized by bubbling with N2 before and after mixing unless otherwise 
stated. The mixtures were diluted to the required concentration with deionized water or 
with 10-50 mM phosphate buffer solution (pH 7.0, purged with N2), bubbled with N2 
again, and then incubated at 310 K in a water bath for the required times for the 
subsequent HPLC and LC-MS analysis or preparative separation. The samples for 
semipreparative separation contained 1-10 mM complex 1 and 5-50 mM GSH. 
For the reaction of complex I with GSH under argon, the separate reactant solutions (pH 
of GSI-1 solutions adjusted to 6.8) were mixed at molar ratios of 0.02:5 mM or 1:10mM 
after deoxygenation by four cycles of freeze-thawing on a vacuum line under Ar, and 
then incubated at 3 10 K for 48 h under Ar bubbling. For the same reactions under 02, 
similar solutions of the starting materials were mixed in air and then incubated at 310 K 
for 48 Ii with 0  bubbling. 
The time-course of reaction of complex 1 (0.3 mM) with GSH (3 mM) in unbuffered 
aqueous solution in air (i.e. not purged with N2), was followed chromatographically by 
injection of aliquots of the mixtures onto the HPLC column at various time intervals. 
Sampling at various times was done in air by briefly removing the cap to extract an 
aliquot. 
3.2.3.3 NMR / FT- ICR MS 
The HPLC fractions from the reactions of complex 1 with various molar ratios of GSH 
in water or in phosphate buffer (pH*  7) were collected from semipreparative HPLC 
separations, and immediately frozen in liquid nitrogen, and then lyophilized. The 
resulting solids were redissolved in 0.6 mL of 10% D20190% H20 for 1D and 2D 
NMR experiments. The pH value (initially pH ca. 2 due to the presence of 
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trifluoroacetic acid) of the fraction containing complex 4 from the reaction of complex I 
with GSH in buffer solution (pH*  7) was immediately adjusted to 7 using NaOH and 
HCI04. The solution was then freeze-dried and redissolved in 90% 1-10/10% D20. and 
the pH was readjusted to 7 before the NMR experiments. The samples for FT-ICR MS 
were diluted from NMR samples. 
A 	10 mM solution of 
5 
 N-labeled complex I ( 15 N-1)was used to follow reactions of I 
with (SFI by ID [' II] and 2D [ 'H,'5N] I1SQC NMR. The reaction mixtures were 
prepared using the same method as that for HPLC samples. 
3.2.3.4 Determination of Extinction Coefficients 
HPLC fractions of complex 1. its aqua and TFA adducts as well as the GSH adducts 
were collected from a 10 mM equilibrium aqueous solution of I, the 2-h and 24-h 
reaction mixtures of complex 1 with GSH in water, 24-h reaction mixture of complex 1 
with GSH in buffer containing 22 mM MCI. The method has been shown in Chapter 
2.7, and the values are listed in Table 3. I. 










[(i 6-bip)Ru(en)Cl](1) 7.72 384 179358 1.00 
[(r-bip)Ru(en(H20)]2 (2) 6.30 312 161914 1.10 
[(11 -bip)Ru(en)(TFA)j (3) 0.89 44.1 23722.9 1.14 
[Oi6-bip)Ru(en)(GS-S] (4) 0.74 36.8 36947.2 2.32 
ft116-bip)Ru(en)(G S-O)] (5) 1.06 52.6 29707.4 1.20 
[(16-bip)Ru(en)(GS-0)](6) 0.89 43.8 25517.4 1.24 
[((r'-bip)Ru)2(GS-S)31 (7) 0.97 47.8 42539.9 1.89 
{(i'-bip)Ru(en)(GS(0)-S)] (10) 0.41 20.3 11160.2 1.17 
a Ru concentration in 5 mL aqueous sample determined by ICP-OES. 
b Relative peak areas of HPLC fractions with UV detection at 254 nm. 
Relative extinction coefficient. 
3.2.3.5 Determination of Free Thiols (SH) in Proteins 
DTNB is a symmetrical aryl disulfide which readily undergoes the thiol-disulfide 
interchange reaction in the presence of a free thiol (see Scheme 3.1): 
Scheme 3.1 Reaction of DTNB with free thiol. The TNB has a relatively intense absorbance at 
412 nm compared to both disulfides. Because the stoichiometry of protein thiol to TNB formed 










CO2H 	 CO2H 	 CO2H 
DTNB 	 TNB 
45 
The DTNB stock solution (2 mM DTNB in 50 mM sodium acetate) and the stock 
solution of Tris buffer (1 M Tris buffer, pH 8) were prepared and kept refrigerated. The 
absorbance of DTNB solution (0.1 mM) in Tris buffer (0.1 M, pH 8) was recorded, and 
the reaction of DTNB (0.1 mM) with GST (15.2 jiM) in Tris buffer (0.1 mM, p1-I 8) was 
followed at 412 nm, 310 K, continuously. The maximum absorbance of the reaction 
mixture was recorded) 16 The concentration of free thiol was calculated using eq. 1: 
Conc. (thiol) = [Abs]412 /13.6 (mM' cm-1) 	 (1) 
where 13.6 mM' cm'is the extinction coefficient of TNB in Tris buffer at 412 nm at 
310 K.116 
The number of free thiol groups included in GST which was used in this Chapter was 
calculated using eq. 2: 
No. (thiol) = [Conc. (thiol)] (jiM) x  4/15.2 (j.tM) 	(2) 
where 4 is present because GST should contain 4 free thiol groups, and 1 5.2 iM is the 
concentration of GST used in the reaction mixture. It is obtained that the number of free 
thiols in the GST used in this Chapter is 2. 
Kel 
3.3 Results and Disscussion 
3.3.1 Reactions of 1 with GSH in Unbuffered Aqueous Solution 
The reaction of complex 1 with GSH in water without adjustment of pH was 
investigated using HPLC, ESI-MS, and NMR spectroscopy. Reaction of 1 (0.3 mM) 
with a 10-fold molar excess of GSH (pH initially Ca. 3) at 310 K gave rise to two 
products as detected by HPLC (peaks d, e in Figure 3.2) after ca. 10 mm, and then 
another product (peak f) after 0.5 h. After 6 h, a forth adduct (peak g) formed and 
increased in concentration until 24 h; meanwhile HPLC peaks d, e, and f decreased in 
intensity. 
ESI-MS analysis of the HPLC fractions (Figure 3.2) gave a singly charged ion peak 
centered at m/z 622.1 for peaks d, e, and f, assignable to (isomers of) monoruthenium 
6 	 +[171 
glutathione complexes 4, 5, and 6 (calcd mlz 622.1 for {(ri  -bip)Ru(en)(GS) + H} ). A 
fragment ion peak at m/z 561.9 resulting from release of en (calcd m/z 562.1 for 
bip)-Ru(GS) + H}) was detectable only for fraction f (adduct 4), which suggests that 
the Ru-N bonds in this complex are weakened as might be the case for an S-bound 
thiolato complex [(16-bip)Ru(en)(GS-S) (4). The trans-tabilizing effect of sulfur is well-
known in Pt11 chemistry. 
[18] 
At low pH (ca. 3.0), the amino group of GSH is protonated 
and unlikely to coordinate to Ru. Therefore, fractions d and e are more likely to 
correspond to Glu or Gly carboxylate-hound species [(( 6 1 -bi p)Ru)(en)(G1 u-Cys-Gly- 
+ 	 6 	 + 
0)] (5) and [((ii -bip)-Ru)(en)(0-Glu-Cys-Gly)] (6). The mass spectrum (Figure 3.3) of 
peak g indicated that this fraction contained a diruthenium glutathione adduct [((i16-bip)- 
Ru)2(GS)3]
2- 






g 	 Time /h 
24 
15 	 25 
Retention Time i mm 
Figure 3.2 	HPLC time-course for the reaction of 1 (0.3 mM) witi 10 mol equiv GI in 
aqueoT solution (pH ca. 	at 310 K. Peak assignments: (a) 1; (b) [(ii -bip)Ru(en)(H20)] (2); 
(c) [(ii -bip)Ru(en)(TFA)] (3); (d, e, f, g, and h) GSH adducts. Peak h appears to be due to 
tetranuclear clusters (discussed later). 
100- {(6-bip)Ru)2(GS)3+4H} 
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Figure 3.3 Mass spectra for HPLC fractions d, e, f and g (see Figure 3.2) from the reaction of 
complex 1 with GSH (0.3: 3 mM) in aqueous solution (pH Ca. 3). 
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Fraction g in Figure 3.2 was also collected from a reaction mixture of complex 1(5 mM) 
with GSH (25 mM) incubated at 310 K for 48 h and was characterized by I D H and 2D 
[' l-I, 'H] NMR spectroscopy (Figures 3.4, 3.5, and 3.6). Only one set of proton 
resonances was observed for the two biphenyl ligands (Figure 3.6, Table 3.3) and one set 
for the three glutathione ligands (Figure 3.4, Table 3.2), which indicates that the two 
biphenyl and three glutathione ligands in this adduct are magnetically equivalent, and 
that adduct 7 [((1 16 -bip)Ru)2-(GS)31 is formed via the substitution of en in [(i 
6 
-bip)Ru-
(en)(GS-S)] (4) by two glutathione ligands. No peaks for en protons (en-NH2 or enCH2) 
were detectable. For the biphenyl groups, five well-separated resonances are observed 
for the ortho (6 7.46, 7.26), meta (5 5.72, 5.83), and para (ô 5.97) protons of the 
coordinated phenyl ring (A), and four peaks for the ortho (6 7.57), meta (6 7.65, 7.51), 
and para (6 7.45) protons of the noncoordinated phenyl ring (B). At pH 2.9, compared 
with free GSH at the same pH value (Table 3.2), the -CH2 and u-CH proton resonances 
of the cysteine residues in adduct 7 are shifted to high field by 0.51, 0.58, and 0.42 ppm, 
respectively, as expected for an S-bound glutathione ligand. The 2D [' H,'H] NOESY 
NMR spectrum (Figure 3.5) shows that there are strong NOEs between the aromatic 
protons of the coordinated biphenyl ring (A) and the u-CH and f3-CH2 protons of the 
cysteine residues in 7 (the assignments for the NMR spectra were carried out with the 
assistance of Dr. Fuyi Wang). 
ICP-OES calibration of HPLC peak areas (Table 3.1) showed that after 2 h of the 
reaction 9% of the Ru was present as 4 and 3 1% as 5 + 6. After 24 h, the dinuclear 
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Figure 3.4 ID 'Hand 2D ['H,'H] TOCSY NMR spectra for HPLC fraction (g) (see Figure 3.2) 
from the reaction of complex 1 with GSH (5:25 mM) in aqueous solution for 48 h at 310 K. 
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Table 3.2 	'H NMR chemical shifts (ô) for GSH and GSH ligands in the adduct [((re- 




7-CH2 2.52 2.59 (0.07) 
13-CH2 2.13 2.19(0.06) 
a-CH 3.79 3.88 (0.09) 
a-NH3 - h - I, 
Cys 
3-CH2 2.95 2.44 (-0.51) 
2.90 2.32 (-0.58) 
u-CH 4.54 4.12 (-0.42) 
ct-NH 8.44 8.51 (0.07) 
Gly 
a-CH2 3.94 3.93 (401) 
ct.-NH 8.48 8.16 (-0.32) 
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Figure 3.5 (A) NOEs between the protons of the biphenyl ligand and cysteine a-CH, p-CH2 
protons of 7, indicating their proximity. (B) Structure of 7 with NOEs indicated by dotted lines; 
the side chains of two of the GS ligands are omitted for clarity. For NOEs between protons of 
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Figure 3.6 NOEs between the phenyl rings of the biphenyl ligands in the thiolato adduct [((T16 
bip)Ru)2(GS)3]2  (7), allowing assignments for resonances of aromatic protons. The ortho proton 
from arene A is correlated with the ortho proton from arene B, and the ortho' proton from arene 
A is correlated with the ortho' proton from arene B (see Figure 3.5(B)). Resonances labelled 
with an asterisk (*) arise from impurity species such as the aqua adduct (2), mono thiolato 
adduct (4), see Figure 3.2. Some of the impurity resonances are overlapped with those of 7, 
which leads to distortion of the signal intensities. For proton labelling, see Figure 3.5. 
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Table 3.3 'H NMR chemical shifts for biphenyl ligands in complex 1 and the adduct [((fl 6_ 
 
bip)Ru)2(GS-j.t-S)3]2 (7) in 90% H20 / 10% D20 (298 K) 
Complex (pH) 
Proton' 	 1 (55)b 	 7(2.9) 
6 
Phenyl ring A 
Ho 5.98 7.46 
Ho' 5.98 7.26 
Elm 6.26 5.72 
Hm' 6.26 5.83 
Hp 5.91 5.97 
Phenyl ring B 
Ho 7.83 7.57 
Ho' 7.83 7.57 
Hm 7.64 7.65 
Hm' 7.64 7.51 
Hp 7.64 7.45 
a For proton labels, see Figures 3.5. 	 b Wang, F. Y.; Chen, H. M.; Parkinson, J. A.; 
Murdoch, P. D.; Sadler, P. J. Inorg. Chem. 2002, 41, 4509-4523. 
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The reaction of complex I with GS1l in unbuffered solution was also studied at 
millimolar concentrations (1:GSH 2:20 mM) at 310 K by 2D [' H, ' N] HSQC NMR 
15 	 15 	 5 
using N-labeled I ( N-I). The spectra are shown in Figure 3.7, and the H and N 
chemical shifts are listed in Table 3.4. The results are consistent with those obtained by 
HPLC. During the early stages (<I h), three pairs of new cross-peaks appeared which 
IS 
are assignable to the N-en ligaiids in adducts 4, 5, and 6. Cross-peaks 5a!b and óalb 
(Figure 3.7) decreased in intensity after ca. 4 h and disappeared after ca. 10, and cross-
peaks 4aIb increased in intensity up to 6 h, and then decreased and disappeared after 13 
h. Because the diruthenium adduct 7 does not contain bound '5N-en, it does not give rise 
to 'H,' N cross-peaks, and therefore no hll/LN  signals were detectable during the late 
stages (>13 h) of the reaction when adduct 7 was the main product (the assignments 
were made with the help of Dr. Fuyi Wang). The two intermediates 5 and 6 were not 
stable long enough in aqueous solution to allow sufficient NMR data to be recorded to 
provide an unambiguous identification of the binding sites. However, the 2D HSQC 
NMR spectra showed two pairs of cross-peaks corresponding to the formation of the 
intermediates 5 and 6 (Figure 3.7), and their 15N-en H/ 
15 
 chemical shifts (Table 3.4; a 
5a 6.241-24.9, 5b 4.231-24.9; 6a 6.141-24.6. 6h 4.18/-24.6) are in a similar range to those 
15 	 6 	 2+ 
for N-en groups in carboxylate-hound adducts of cystine [(ii. -bip)Ru(en)(Cys2H2-O)I 
6 	 + 
(5 6.071-24.7, 4.12/-24.7), cysteine [(,q-bip)Ru(en)(L-CysH-O)} (5 6.08/-24. I, 4.08/- 
['9] 	 ['01 
24.1) and acetate (ö 6.061-25.6, 4.131-25.6). 
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Figure 3.7 2D ['H, '5N] HSQC NMR time course for the reaction of '5N-1 (2 mM) with GSH 
(10 mM) in 90% H20 / 10% D20 at 310 K over 24 h. After 13 h reaction, no cross-peaks were 
detectable. Assignments: lalb complex 1 ([( 6-bip)Ru('5N-en)Cfl, 2aJb aqua complex 2 ([(16 
bip)Ru('5N-en)(H20)]2 ), 4a/b, 5a/b and 6aTh GSH adducts 4, 5 and 6 ([(16-bip)Ru('5N-
en)(GS)]). No cross-peaks are observed for the diruthenium adduct 7 ([((i16-bip)Ru)2(GS)3]2 ) 








Table 3.4 'H, '5N NMR Peaks Observed for Reactions of 5N-1 (2 mm) with GSH (20 mM) in 
90% H20/10% D20 (pH* Ca. 2.9, Figure 3.7) at 310 K 
complex 
	 (peak) 6 IH/15N 
I 	 (I a) 6.097-24.62 (1 b) 4.05/-24.62 
2 	 (2a) 6.30/-23.06 (2b) 4.26/-23.06 
4 	 (4a) 5.681-27.74 (4b) 3.607-27.74 
5a 	 (5a) 6.241-24.92 (Sb) 4.23/-24.92 
60 	 (6a) 6.147-24.60 (6b) 4.18/-24.60 
a 
 Assignments for 5 and 6 are ambiguous. 
Chloro Ru
11 
 arene complexes such as complex 1 undergo rapid hydrolysis with half-lives 
ranging from 5 to 10 min. 211  In aqueous solution, in the presence of nucleophiles such as 










 (5) and [(ii -bip)Ru(en)(O-Glu-Cys- 
Gly)] (6) are kinetically favored products from reaction of 1 with 10 mol equiv of GSH 
6 	 2+ 
and are formed via displacement of the aqua ligand in [(ri -bip)Ru(en)-(H20)] (2) 
6 	 2+ 
(Scheme 3.2). However, sulfur-coordination of thiolate to {(71-bip)Ru(en)} appeared 
to be thermodynamically favored, and the thiolato adduct [(i16-bip)Ru(en)(GS-S)] (4) 
became the dominant product after 6 h. Subsequently, the en ligand of 4 was readily 
released assisted by en protonation, by the trans-labilizing effect of S-bound glutathione 
and binding of two other S-bound glutathione ligands, giving the triply S-bridged 
diruthenium thiolato complex [((rl6-bip)Ru)2(GS-1u-S)3] (7). This reaction pathway is 
similar to that observed previously for reaction of L-cysteine with 1.[19] 
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Scheme 3.2 Pathways for Reactions of Complex 1 with GSH for 24 h at pH 3 
[( 6-bip)Ru(en)CI] (1) 	 [( 6-bip)Ru(en)(0H2)]2 (2) 
pH 3 1 GSH, air 
[(q6-bip)Ru(en)(GSH-0)] (5,6) 
+ 
(( 6-bip)Ru(en)(GS-S)] (4) 
'I, 
{[(q6-bip)Ru12(GS-p-S)31}2 (7) 
In unbuffered solution (pH ca. 3) and at 310 K, ruthenium arene anticancer complex 1 
reacted with 10 mol equiv GSH for 48 h, giving rise to two di-ruthenium glutathione 
complexes as main products (Figure 3.8) of which the diruthenium triply-S bridged 
product has been identified by conventional LC-ESI MS and NMR. 
13.99 
10 	 15 	 20 
Retention Time/mm 
Figure 3.8 HPLC chromatogram with UV detection at 254 nm for the reaction of 1 and GSH 
(2:20 mM) in unbuffered solution (pH -3) at 310 K for 43 h. The peak centred at 13.99 mm 
corresponds to the S-bridged di-ruthenium glutathione adduct [((16-bip)Ru)2(S-GS)3]2 (7). 
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The fraction centred at 17.25 min was collected and concentrated for ESI-MS (Figure 
3.9) and ID 'H, 2D ['H,'H] NMR (Figure 3.11 and 3.12) experiments. A singly-charged 
ion peak centred at m/z 1824.2 and a doubly-charged ion peak centred at m/z 913.2 were 
assigned to a di-ruthenated adduct 8 according to the patterns of the ion peaks (Figure 
3.10). Two singly-charged fragment ions at m/z 1485.2 and 1146.3 appear to correspond 
to release of one and two sulfinate (GS022 ) ligands, from the di-ruthenated adduct, 
respectively (Figure 3.9), which indicates that at least two GS022  ligands are involved in 
this adduct. Due to the pH value for the reaction of 1 with GSH in water was ca. 3, the 
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Figure 3.9 ESI mass spectrum with a cone voltage of 50 V for HPLC fraction centred at 17.25 
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Figure 3.10 	Isotopic simulations for mono-ruthenium with one plus charge (top) and di- 
ruthenium with one plus charge (bottom). 
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Only one set of proton resonances was observed for the two biphenyl ligands (Figure 
3.12, Table 3.6), and one set for the glutathione ligands (Figure 3.11, Table 3.5). Due to 
the oxidation of sulfur in the Cys, the proton resonances for Cys-CH and Cys-Cl-12 could 
not observed (Figure 3.11), and the signals for these two proton resonances probably 
shift and are covered by the water signal. The significantly different chemical shifts of 
ct-CH and 13-CH2 in the cysteine part of GSH between 8 and unbound GSH (Table 3.6) 
indicated that Ru(II) arene anticancer complex 1 binds to GSOH and GS02H both via 
Ru-S. Because it is a di-ruthenated complex, the pattern of the proton resonances for the 
biphenyl ligand was not very clear, but they were still assigned according to the 
correlations shown in the NOESY spectrum (Figure 3.12). Therefore, the ESI-MS and 
NMR results showed that the two ruthenium centres are equivalent and that the 
ethylenediamine chelate ligand has gone. The HPLC fraction eluted from 10.93 to 12.24 
min could not be separated although the gradient was changed to improve the separation, 
and the concentration of multinuclear ruthenium clusters in the fraction eluted from 
10.93 to 12.24 min was too low to allow good ESI MS analysis. Therefore, ESI-FT-ICR 
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Figure 3.11 	ID 'H and 2D ['H,'H] TOCSY NMR spectra for HPLC fraction centred at 17.25 
mm (see Figure 3.8) from the reaction of 1 with GSH (2:20 mM) in unbuffered solution (pH -3) 
at 310 K for 43 h. 
Table 3.5 'H NMR chemical shifts (6) for GSH and GSH ligands in the di-ruthenated adduct 8 
in 90% H 20/10% D20 (298 K, pH 2.9). 
Proton GSH 8 
Glu 
2.52 2.48 (-0.04) 
j3-CH2  2.13 2.17 (0.04) 
(Y.-CH 3.79 3.84 (0.05) 
a-NH3 h h 
Cys 
13-CH 2  2.95 
290 -" 
u-CH 4.54 -C 
a-NH 8.44 8.42 (402) 
Gly 
3.94 3.92 (402) 
a-NH 8.48 8.33 (-0.15) 
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Figure 3.12 	(A) NOEs between the phenyl rings of the biphenyl ligands in the di-ruthenated 
adduct 8, allowing assignments for resonances of aromatic protons; (B) Structure of biphenyl 
ligand with NOEs indicated by dotted lines. The ortho proton from arene A is correlated with 
the ortho proton from arene B, and the ortho' proton from arene A is correlated with the ortho' 
proton from arene B. 
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Table 3.6 	'H NMR chemical shifts for biphenyl ligands in complex 1 and the di-ruthenated 
adduct 8 in 90% H20 / 10% D20 (298 K) 
Proton' 
Complex (pH) 
1 (55)b 	82.9) 
6 
Phenyl ring A 
Ho 5.98 6.26 
Ho' 5.98 6.18 
Hm 6.26 5.86 
Hm' 6.26 5.86 
Hp 5.91 
Phenyl ring B 
Ho 7.83 7.73 
Ho' 7.83 7.73 
Elm 7.64 7.49 
Hm' 7.64 7.49 
Hp 7.64 7.49 
a For proton labels, see Figures 3.12. 	
b Wang, F. Y.; Chen, H. M.; Parkinson, J. A.; 
Murdoch, P. D.; Sadler, P. J. Inorg. Chem. 2002, 41, 4509-4523. 	Not observed 
Me 
The HPLC fraction eluted from 10.90 to 12.50 mm (see Figure 3.8) was collected for the 
analysis using 'H NMR spectroscopy. Compared to the 'H NMR spectra for a di-
ruthenated tri-glutathione adduct {[(16-bip)Ru]2(GS-t-S)3}2 (7) involved in the HPLC 
fraction eluted centered at 13.99 min in Figure 3.8 and the di-ruthenated adduct 8 
obtained from the HPLC fraction eluted centered at 17.25 min in Figure 3.8, the 
biphenyl proton signals obtained from the 'H NMR spectrum for the HPLC fraction 
eluted from 10.90 to 12.50 min in Figure 3.8 were too broad to observe (Figure 3.13), 
which may illustrated that the oxidation states for two ruthenium atoms in complex 8 are 
+2 or 0, and oxidation states for some Ru atoms in the complex of which spectrum is 
shown in Figure 3.13(C) may be +1 or +3, because Ru(l) and Ru(Ill) are 
paramagnetic [231 which causes the signals for protons close to Ru to become very broad.. 
(C) 
7.8 	7.6 	7.4 	7.2 	7.0 	6.8 	6.6 	6.4 	6.2 	6.0 	5.8 	
ppm 
Figure 3.13 'H NMR spectra for a di-ruthenated tri-glutathione adduct 7 (A), the di-ruthenated 
adduct 8(B) and the HPLC fraction eluted from 10.90 to 12.50 min in Figure 3.8 (C). 
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In order to identify the multinuclear ruthenium glutathione product unambiguously by 
MS, the NMR sample of the di-ruthenated complex 8 was analysed by FT-ICR MS, and 
a range of doubly-charged ion peaks and two triply-charged ion peaks were observed 
(Figure 3.14(A), Table 3.7). A doubly-charged ion peak centered at m/z 921.1 was 
assigned to {[(16-bip)Ru(GS02)12 - 20 + 10 H}2 , corresponding to a di-ruthenated 
glutathione adduct {[(r16-bip)Ru(GSO2)]2}8  (8) according to the MS isotopic simulation 
(see Figure 3.14(B)). A doubly-charged ion peak centered at m/z 848.2 and a triply-
charged ion peak centered at m/z 565.8 are assignable to release one glutamate acid part 
and three oxygen atoms from the adduct 8. Also the HPLC fraction eluted from 10.93 to 
12.24 min was collected for FT-ICR MS analysis. A series of doubly-charged and triply-
charged ion peaks were obtained (see Figure 3.15(A) and (B)). The doubly-charged ion 
peak centered at m/z 1189.2 was assigned to {[(r 
6  -bip)Ru(GS02)]4 + 4 H}
2+ 
(corresponding to a tetranuclear complex {[(fl6-bip)Ru(GSO2)]4}2 (9)) based on the 
isotopic simulation (Figure 3.15(C)). The assignments of all the MS ion peaks in Figure 
3.14(A), 3.15(A) and (B) were listed in Table 3.7. The proposed structures of complexes 
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Figure 3.14 (A) FT-ICR mass spectrum for the di-ruthenated complex 8; (B) MS isotopic 
simulations for ion peaks centered at m/z 921.1 and 912.7. 
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Figure 3.15 (A) and (B) FT-ICR MS for the HPLC fraction eluted from 10.93 to 12.24 min as 
shown in Figure 3.8; (C) Isotopic simulations for the ion peaks centered at m/z 1189.2 and 
1083.6. 
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Table 3.7 The mass-to-charge ratios of the most abundant isotopomer of the ion fragments from 
the ruthenium sulfinate/sulfenate gi utathione adducts { [(116-bi p)Ru(G SO2)2]2 8-  (8) and {[(116_ 
bip)Ru(GS02)14} 2-  (9) detected by direct infusion ESI-FT-ICR MS. 
Adduct I 	m/z 	 Ion 
8 556.7662 {8_Glufl_Glyb+IIHC}3+ 
565.7668 {8—Glu-30+ 11H}3  
609.1334 {8-30+IIH}3  
665.0882 {8—Giu—Gly—GS02 + 1OH}2 
834.6312 {8—Glu--Gly+ 10H}2 
848.1573 {8—GIu-30+ I0H}2 
912.6801 {8-30+10H}2 
722.4247 {9—GIu--50+5H}3 
781.7766 f9-20+5H' )3+ 






1181.1743 f9-0+4H )2+  
1189.1709 {9+4H}2 
a  Indicates loss of a Glu residue H02CCH(NH2)CH2CH2CO (C51-1803N). 	b Indicates loss of a 
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Chart 3.1 Proposed structures of tetra- and di- ruthenium glutathione sulfinate adducts. The 
exact nature of the bridges between the ruthenium atoms in these clusters is unknown. 
A reaction mixture of complex I with GSI-I (2:20 mM) in unbuffered 66.6% 180-labelled 
water incubated at 310 K for 48 h was analysed using nano LC-nanoESl-FT-ICR MS 
method described above. Two peaks appeared in the TIC chromatogram (Figure 3.16) 
and the mass spectra for the fractions eluting at 18.2 and 22.6 min are shown in Figure 
3.17. The isotopic simulations (Figure 3.18) indicate that the fractions contain a tetra-
and a di-ruthenium sulfinate/sulfenate glutathione complexes, respectively, of which the 
Me 
oxygen atoms in sulfinate and sulfenate ligand were 180.  FT-ICR MS was applied to the 
unambiguous determination of iron atom oxidation in a metalloprotein by matching 
experimental and theoretical isotopic abundance mass distribution. 24' The good fit 
between the experimental mass isotopic peaks and theoretical isotopic simulations 
(Figure 3.18) showed the oxidation states for the two Ru atoms in 8 may be zero, and the 
oxidation states for two Ru atoms in 9 may be +1 and the other two may be still +2. 
5 	15 	25 
Retention Time I mm 
Figure 3.16 TIC chromatogram for the reaction of! with GSH (2:20 mM) in unbuffered 66.6% 
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Figure 3.17 FT-ICR mass spectra for fractions at specific retention time (RT) of LC peaks f 
and g from the reactions of 1 and GSH 2:20mM in 66.6% "O-labeled water (pH 3) at 310 for 
48 has shown in Figure 3.16. 
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Figure 3.18 Isotopic model (dots, of which the values of X and Y correspond to the m/z and 
intensity of the respective isotopic ion peak) and mass spectral (lines) for fragmented ions of 
arene ruthenium 80-labelled sulfinate/sulfenate glutathione adducts (A) {[(T 6-bip)Ru(S-
GS'80,)]4 - Glu - 518Q + 4H}2 ([C83H9602 803S4N11 Ru(H)2 Ru(T)2 J2 ) and (B) {[(r16-bip)Ru(S-
GS1802)]2 - 3 180  + 1OH}2 ([C64H920241805S4N12 Ru(0)2]2 ). The simulation was carried out by 
Mr. Stefan Weidt. 
Also under argon, the reaction of 1 with GSH under physiologically-relevant conditions 
(the result is shown in Figure 3.25 in 3.3.2) gave rise to the di-ruthenated glutathione 
sulfenato/sulfinato adduct 8, which illustrates that the oxygen atoms in sulfinate and 
sulfenate ligands of the di-ruthenated adduct 8 arise from solvent water. Water cannot 
act as an oxidant, so the function of water is only providing oxygen atoms in this 
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reaction. A similar contribution of water has been found in the oxidation of NHase by 
Cpx. 251 The thiol group in GSH is proposed to reduce the Ru(II) complex to Ru(0), and 
the redox reaction occurred between ruthenium atoms and sulphur atoms, in which 
Ru(+2) was reduced to Ru(0) while S(-2) was oxidized to S(0) and S(+2). Such similar 
redox reaction has been observed in the reactions of trans, cis-{Pt(en)(OH)212] with 
rHA.1261 Similarly, for complex 9, when GS(-2)l-1 was oxidized to GS(+2)02H by Ru(II) 
(Ru(+2) is reduced to Ru(+l)), oxygen atoms are provided from the solvent H20 as 
shown by FT-ICR MS combined with 180-labelling experiments. The oxidation states of 
the sulfurs is given in Scheme 3•3[26J  The formation of Ru-Ru bonds, Ru-S bonds and 
Ru-S-Ru bonds as well as determination of the oxidation states of Ru atoms require the 
use of other technologies such as EXAFS for identification. 
Scheme 3.3 Major pathways for thiol oxidation with oxidation states of sulthur, reproduced from 
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Ruthenium(0) arene complexes are usually useful catalysts for hydrogenation, 
[27,281 
isomerization,129' and dimerization (301  reactions of alkenes. The dinuclear Ru(0) arene 
complex with sulfenate (SO) bridges is reported here for the first time; whereas some 
multinuclear Ru(II) complexes with sulfur monoxide (SO) or sulfur dioxide (SO2) 
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bridges, like Ru6C(CO)1 00) and Ru6C(CO)17(S02), have been demonstrated 
before. 311 The diruthenium complex 8 may play a similar role to that of the mono- 
ruthenated sulfenate glutathione adduct [(TI 	in the competitive 
reactions of 1 with GSH and guanine in DNA (see Chapter 4). 
Few investigations of ruthenium(l) complexes have been reported. 1321 Ru(I) complexes 
have shown very promising catalytic activities in hydrogenation and carbonylation of 
organic substrates, [33-361  and dinuclear Ru(l) complexes have unusual edge-sharing 
bioctahedral structures which stretch to other bridging anionic groups like pyrazolato or 
thiolato ligandsJ37391  
3.3.2 Reactions of 1 with GSH under Physiologically-relevant 
Conditions 
The reaction of complex 1 (20 iiM)  with 250 mol equiv of GSH was studied in at 
physiologically-relevant conditions (the conditions similar to those which might be 
present in cells: micromolar Ru concentrations, in pH 7 phosphate buffer containing 22 
mM NaCl (the cytoplasmic concentration of chloride)1401) at 310 K.1411 To minimize the 
content of 02,  all starting solutions were purged of air by bubbling with N2 before and 
after mixing. 
The reaction course was different from that described above for unbuffered reactions. 
During the early stages (<12 h), HPLC peak i was dominant, but later (48 h) peak j 
increased in relative intensity (Figure 3.19). The mass spectrum of fraction i (Figure 
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3.20(A)) is identical to that of fraction f from the reaction of 1 with GSH in unbuffered 
aqueous solution (Figures 3.2 and 3.19), and corresponds to the thiolato adduct [(16W 
bip)Ru(en)(GS)] (4). A fragment ion MS peak at m/z 562.3 corresponding to release of 
the en ligand from this complex is observed, suggesting that S-bound glutathione can 
labilize the en ligand in 4. For fraction j, a singly charged ion peak at m/z 638.3 was 
observed, corresponding unexpectedly to the sulfenato complex [(
6
11 _bip)- 
Ru(en)(GS(0))} (10) (calcd m/z 638.1 for {( 
6 
-bip)Ru(en)-(GS(0)) + H)'), 
accompanied by a singly charged ion peak at m/z 324.0 corresponding to the release of 
the fragment {GSOH + 2H} (calcd m/z 324.1; Figure 3.20). The amount of 10 in the 
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Figure 3.19 HPLC chromatograms recorded 12 and 48 h after the start of the reaction of 
complex 1 (20 pM) with a 250-fold molar excess of GSH in phosphate buffer (pH 7) containing 
22 mM NaCl at 310 K. Peak assignments: (b) aqua adduct [(ii6 
	 2+ 
-bip)Ru(en)(H20)} (2); (i) 
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Figure 3.20 Mass spectra for HPLC fractions i and  (see Figure 3.19) in different m/z regions. 
It is notable that the mass spectrum for fraction i is the same as that for fraction f obtained from 
the reaction of 1 with a 10-fold molar excess of GSH at pH ca. 3 (see Figures 3.2 and 3.3). 
From a reaction mixture containing complex 1 (1 mM) and GSH (25 mM) which had 
been incubated at 310 K for 24 h, the thiolato adduct [( 6 11 -bip)Ru(en)(GS)] (4) was 
isolated by preparative HPLC and characterized by JD and 2D 'H NMR spectroscopy. 
The pH*  of the HPLC fraction was adjusted to 7, and after lyophilization the sample was 
dissolved in 90% H20/10% D20 for NMR study. In the 2D [' H, ' H] COSY (Figure 3.21) 
and NOESY (Figure 3.22) NMR spectra, three sets of proton resonances are observed, 
assignable to the glutathione, biphenyl, and en groups. The chemical shifts for the 
former two groups are listed in Tables 3.8 and 3.9. respectively. It can be seen that 
ruthenium coordination induces large changes in the chemical shifts of the Cys f3-CH2, 
a-CH, and u-NH protons of the thiolate ligand. The signals of two CH2 protons separate 
into two quartets (ô 2.96, 2.81), and the resonances of a-CH and u-NH protons are 
shifted to high field by 0.16 and 0.14 ppm, respectively, compared with those of the free 
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peptide. Strong NOEs signals are observed (Figure 3.23), corresponding to the 
interaction of the f3-CH2 protons with the protons of the coordinated phenyl ring (A) (the 
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Figure 3.21 ID 'H and 2D ['H,'H] COSY NMR spectra for HPLC fraction (i) (see Figure 3.19) 
from the reaction of 1 with GSH (5:25 mM) in phosphate buffer (pH 7) containing 22 mM NaCl 
at 3 10 K for 24 h. 
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Table 3.8 	'H NMR chemical shifts (6) for GSH and GSH ligands in the adduct 
[(6 
bip)Ru(en)(GS-S)] (4) in 90% H 20110% D20 at pH 7 (298 K) 
proton  
y-CH2  2.52 
f3-CH2  2.13 
a-CH 3.74 
a-NH3 h 




















a Aô = c (4) - 6 (GSH). 
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Figure 3.22 NOEs between the phenyl rings of the biphenyl ligand in the thiolato adduct R1 6-
bip)Ru(en)(GS-S)J (4), allowing assignments of peaks for aromatic protons. For proton labelling, 
see Figure 3.23. 
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Table 3.9 'H NMR chemical shifts for biphenyl ligands in complex 1 and the adduct [(11 6_  
bip)Ru(en)(GS-S)] (4) in 90% H20 / 10% D20 (298 K) 
Complex (pH*) 
Proton' 	 1 (55)b 	 4(7.3) 












a  For proton labels, see Figures 3.23. 	 b  Wang, F. Y.; Chen, H. M.; Parkinson, J. A.; 
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Figure 3.23 (A) NOEs between the biphenyl and Cys 13-CH2 protons in complex 4, indicating 
their proximity (<ca. 5 A apart). (B) Structure for 4 with NOEs indicated by dotted lines. For 
NOEs between protons of the two phenyl rings, see Figure 3.22. 
HPLC and MS studies (Figures 3.24 and 3.25) showed that the thiolato adduct 4 is not 
stable in air at pH 7, but is converted to the sulfenato complex 10, instead of into the 
dirutheniurn thiolato complex [((1 '6  -hip)Ru)2(GS)31 (7) as at pH 3. This instability was 
first observed over a period of 3 d while NMR spectra of an HPLC-isolated sample of 4 
(pH* 7) were being recorded; during that time 52%[42]  of 4 transformed into 10 (Figure 
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Figure 3.24 HPLC chromatogram with UV detection at 254 nm for an HPLC-isolated sample of 
the thiolato adduct [(116-bip)Ru(en)(GS-S)] (4), obtained from the reaction of complex 1 with 
GSH (1:10 mM) in phosphate buffer (pH 7) containing 22 mM NaCl at 310 K for 24 h, after 
standing for 3 d whilst NMR spectra were recorded. The partial oxidation of the thiolato 
complex 4 (peak i) to the sulfenato complex [(TI 6 	(10) (peak j) is evident. 
A comparison was also made between the HPLC profiles for reactions carried out under 
02 and under argon (Figure 3.25(A)). For reactions under 02,  the sulfenato product 8 
was dominant, and little of 4 remained after 48 h reaction; however, under Ar the 
thiolato adduct 4 was dominant, and little of 10 was formed, which strongly suggests 
that the sulfenate arises from oxidation of the thiolato complex and that the oxygen atom 
in the sulfenate originates from 02.  For the reaction under Ar, two new HPLC peaks 
with retention times of 16.60 and 17.04 min were observed, labeled I in Figure 3.25. The 
mass spectrum of fraction I (Figure 3.25(B)), separated from a mixture of 1 mM 1 and 
10 mM GSH in pH 7 buffer containing 22 mM NaCl at 3 10 K which had reacted for 48 
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h under Ar, suggested that it may contain a novel diruthenium thiolato/ sulfinato adduct 
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Figure 3.25 (A) HPLC chromatograms for reactions of complex 1 (20 duM) with a 250-fold 
molar excess of GSH in phosphate buffer (10 mM, pH 7) containing 22 mM NaCl under 02 
2+ 
(bottom) or Ar (top) at 310 K for 48 h. Peak assignments: (b) [(ii
6 
 -bip)Ru(en)(H20)] (2); (i) 
thiolato adduct 4; U) sulfenato adduct 10; (1) dinuclear adduct 8. (B) Mass spectrum for HPLC 
fraction I containing the adduct 8. 
Scheme 3.4 Pathways for Reactions of Complex 1 with GS1-I at p1-1  7 
(( 6-bip)Ru(en)CI] (1) 	 [( 6-bip)Ru(en)(OH2)]2 (2) 
pH7GSH,02 	 W71 GSH,Ar 
(( 6-bip)Ru(en)(GS(0)-S)] (10) 	(( 6-bip)Ru(en)(GS-S)] (4) 
83 
Sulfenic acids are generally too reactive to isolate, 
[43j 
 but a few examples are known in 
.11 which they are stabilized by binding to transition metal ions such as Co
iii ' [44] Ni ,[41  
Ruwhl,[461 Rh ,1471 and Ir.1481 The sulfenato complex 10 obtained here is a new example 
of the stabilization of a sulfenate by coordination to a transition metal. In principle 
binding of the sul!ènate to Ru"  could occur through sulfur or oxygen. In the reported X-
ray structures of RU 
11 
 and Ru"  sulfenate complexes, the sulfenate is S-bonded.1461 A 
similar situation exists for sulfoxides, for which S-bonding is common, although both 
modes of 	
[49] 
binding are known. 	It seems likely that the preferred mode of binding of 
glutathione sulfenate in {(q6-hip)Ru(en)-(GS(0))] (10) is also through sulfur, as 
suggested by the SO stretching frequency (vide infra). 
A characteristic infrared S0 stretching frequency of 10] 8 cm was observed for 10 by 
Dr. Fuyi Wang (data not shown), a frequency similar to those reported for the S-bonded 





[CpW(CO)3(CH2S(0)Me)] (1017 cm 
-I ISOI 	 -! 
) and not nearly so low as the 855 cm found 
for the O-sulfinates (y(SOlr 	
[48]
)) in complex lr(O-02S-p-tolyl)(CO)(PPh3)2 	evidence 
for S coordination in the sulfenate 10. 
In the process of oxidation of thiolate, sulfenate can he further oxidized to sulfinate 
(Scheme 35)•[5h]  However, in the reaction of 1 with GSH at pH 7, the oxidation of 
thiolate stays at sulfenate due to the presence of GSH which acted as reductant. 
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3.3.3 Reactions of 1 with GST in Tris Buffer 
The reaction of complex 1 with GST in Tris buffer (pH 8) was investigated using UV-
Vis and FT-ICR MS. Compared to the spectrum of GST (blue trace in Figure 3.26), the 
spectra for the reaction of 1 (80 p.M) with GST (20 M) in Tris buffer (pH 8) at 310 K 
showed that the absorption for the band of 278 nm decreased as the time passed (see 
Figure 3.26). The band is due to the effects of conjugation of adjacent benzene 
chromophores, the spectrum of biphenyl above 185 nm consists of two broad and 
intense bands at 202 nm and 248 nm. 521 CT transitions Ru - C6H6 (transitions from the 
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Figure 3.26 UV-Vis time course for the reaction of 1 (80 1iM) with GST (20 1iM) in Tris 
buffer (pH 8) at 310 K except for the blue trace (see the labels in the Figure). 
The GST protein was synthesized, purified and identified by Ms. Ann Marie Reid 
using FT-ICR MS (data not shown), and the molecular weight for the GST used in 
this work was confirmed as 27482 Da. 1151 The reaction mixture of 1 (80 [tM) and 
GST (20 pM) in Tris buffer (pH 8) at 310 K for 6 h was analysed by Mr. Stefan 
Weidt using FT-ICR MS, and an ion peak centred at m/z 1172.31 with 24 positive 
charges was detected, assignable to a di-ruthenated GST adduct 11 {[(il -
bip)Ru(en)12(GST)+22H}24 (Figure 3.27), and no sulfenate or sulfinate products 
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Figure 3.27 FT-ICR mass spectrum for the reactions mixture of 1 (80 tiM) and GST (20 
1xM) in Tris buffer (pH 8) at 310 K for 6 h. 
There has been a rapidly growing interest in the redox behaviour of cysteine residues 
in peptides and proteins in recent years. Sulfur has several different oxidation states 
(as shown in Scheme 3.3) in biological systems, and it takes part in many diverse 
redox reactions. 54'551 Previous work has shown that after ruthenium complex 1 binds 
to GSH, an oxygen atom is easily added to oxidize the thiolato adduct to the 
sulfenato adduct which provides a facile route for displacement of S-bound 
glutathione by guanine N7. 171  Therefore, in the presence of air, the ruthenated GST 
adduct 11 is probably oxidized to the corresponding sulfenato adduct by 02 or H202 
(mild oxidant), which will change the function of GST. Even if the sulfenato adduct 
is easily substituted by guanine bases in DNA and RNA, formation of sulfenic acids 
in protein plays a role in enzyme catalysed oxidations due to protein sulfenic acids 
are good electrophilic centres which are well suited for participation in oxidative 
catalysis, [56]  redox regulation, (571  and redox signalling. [581 
87 
3.4 Summary 
Cells contain high (millimolar) concentrations of the tripeptide glutathione which has 
several binding sites for metal ions: the amino and carhoxylate groups at the Glu 
terminus, carhoxylate at the Gly terminus, and thiolate sulfur of the central Cys 
residue. Binding to the deprotonated arnide nitrogen of Cys is possible when a N/S 
chelate ring can be formed, as has been observed for platinum amine complexes. 
[59]  
For heavier, "soft" transition metal ions, thiolate sulfur is a particularly strong site, 
and for Pt", such bonds are essentially formed irreversibly. Elevation of GSH levels 
therefore provides cells with detoxification and resistance mechanisms. The aim of 
this work was therefore to investigate reactions of the organometallic Ru"  arene 
anticancer complex [(lbbip)Ru(en)CflF  with USIl. The strategy involved separation 
of the products by HPLC and identification by ESI-MS. and after preparative IIPLC, 
characterization by N MR spectroscopy. ' N-laheling of the chelated ethylenediarnine 
ligand and use of 2D [IH,bNi  HSQC NMR spectroscopy was helpful for elucidation 
of some of the complicated reaction pathways. 
First reactions were studied at 310 K (body temperature) in unbuffered aqueous 
solution, since buffers themselves usually contain potential ligands. Hydrolysis of 1 
was followed by initial binding to the carboxylate sites and then to the thiolate sulfur 
(Scheme 3.2), but at this acidic pH (3) displacement of en by further S-bound GSH 
ligands was favorable, and, after 24 h, the major product was the dinuclear S-bridged 
complex [((i 6-bip)Ru)2(GS-p-S)3]2 (7). Ruthenium arene complexes induce oxidation 
of coordinated glutathione to give rise to two multinuclear complexes as the main 
products which were unambiguously identified as a diruthenium sulfinate/sulfenate 
complex 8 and a tetraruthenium sulfinate complex 9, respectively, though the metal 
oxidation state and coordination model will need to be confirmed by further 
experiments. With '80-labelled water as solvent, FT-ICR MS analysis indicated that 
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all oxygen atoms in sulfenate and sulfinate products arise from water, implying that 
water may be involved in the oxygenation of cysteine-sulfur in biological signalling 
processes. The developed method will be helpful to investigate the oxygenation of 
cysteinyl groups in thiol-containing proteins resulting from coordination of 
ruthenium anticancer complexes. Although ruthenium(0) complexes have been 
widely used as catalysts, [27-301  the di-ruthenated complex 8 studied in this work may 
play an important role in the biological reactions of Ru(II) arene anticancer 
complexes. 
Subsequent reactions were studied at pH 7 using phosphate buffer in the presence of 
a typical cytoplasmic concentration of chloride (22 mM) and at Ru concentrations 
relevant to cytotoxicity (micromolar). Here, in N2-purged solutions, the S-bound 
adduct [(i 6-hip)Ru(en)(GS-S)] (4) was the major product, and there was little 
tendency for loss of the en ligand. However, unexpectedly, complex 4 was very 
sensitive to the presence of air and underwent oxidation to the sulfenato complex 
ftr16-bip)Ru(en)(GS(0)-S)] (10). 
When reactions were carried out in an atmosphere of 02,  the sulfenato complex 10 
was the main product, suggesting that the oxygen atom in the sulfenate ligand arises 
from 02.  Intriguingly, reactions carried out under strictly anaerobic conditions under 
Ar gave rise not only to the expected thiolato adduct 4 but also to an apparent 
dinuclear complex 8 as well as obtained in the reaction in unbuffered water. 
Preliminary studies on reactions of 1 with GST protein in Tris buffer (pH 8) were 
undertaken. The reaction of 1 with GST (80:20 1iM) in Tris buffer (pH 8) gave rise to 
a di-ruthenated GST adduct 11, and further investigation of the oxidation of 11 to a 
sulfenate/sulfinate adduct and effect on the biological functions of GST will need, 
such as detoxication of the cell against toxic and carcinogenic compounds, and 
cellular mechanism of drug resistance. 
Due to the formation of sulfenato/sulfinato adducts for these ruthenium arene 
complexes which is not observed for Pt anticancer complexes in the reactions of 1 
with GSH under the physiologically-relevant conditions (phosphate buffer, pH 7, 22 
mM NaCl) at 310 K, further investigations on the competitive reactions of 1 with 
GSH and cGMP/DNA oligonucleotides under physiologically-relevant conditions 
will be described in Chapter 4. 
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cGMP/oligonucleotides for a 








 -arene)Ru(Il)(en)ClI[PF6] (en = ethyl enediamine), which 	exhibit 	a 	high 
selectivity for binding to N7 of guanine (G) bases on DNA oligomers)" DNA 
platination is thought to be a key event in the mechanism of action of platinum 
anticancer drugs such as cisplatin,t21 whereas the interaction of platinum species with 
sulfur-containing biomolecules has been associated both with negative phenomena (such 
as toxic side effects and the development of resistance) and with positive effects (such as 
delivery of active species to cells and/or serving as a drug reservoir for ultimate 
platination of DNA) J31 The competitive reactions of N-donor (GN7DNA)  and S-donor 
(thiol/thioether) ligands for Pt"  have been widely studied J41 However, those between Ru"  
arene anticancer complexes, N-donor nucleotides, and S-donor amino acids and peptides 
are largely unexplored, although it has been shown that both cysteine and methionine 
can form S-bound adducts with [( 6-bip)RuCI(e11)][PF6] (1; hip = biphenyl).[ 51 In this 
work, cGMP was chosen as a model nucleotide for investigating competitive reactions 
with glutathionc and complex I because it is a diester as are the nucleotides in DNA and 
RNA. 
The aim of this Chapter is to gain insight into the competition between the glutathione 
and guanine for these Ru(1l) arene anticancer complexes under physiologically-relevant 
conditions. This will involve for cGMP work: micromolar Ru concentrations. milliniolar 
GSH concentration, pH 7, 22 mM NaCl; for DNA oligonucleotide work: micromolar Ru 
concentrations, milliniolar GSH concentration, p1-I 7, 4 mM NaCl. The glutathione (y-L-
GIu-L-Cys-Gly; GSH) is an abundant (millimolar) intracellular thiol responsible for the 
detoxification of heavier transition metal ions, including some platinum and ruthenium 
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anticancer complexes. 3'61Guan0sine3 '5 
'-cyclic monophosphate (cGMP structure is 
shown in Figure 4.1) is a phosphate diester, as are the nucleotides in DNA and RNA. In 
s  this work. two Ru(1l) arene anticancer complexes with different 116-arenes ([(i - 
bip)RuCI(efl)I[PFo] (1) and [(116_tha)RuC1(efl)[PF6] (12 tha = t
etrahydroanthracefle)) were 
studied. Interestingly, it is shown that the Ru-S bond can be substituted by a Ru-N 7 








OF 0 OH 	NH2 
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6-hip)RuCI(en)][PF6I (1), ' N-labe!ed 1 ( '5N-1) and {(q6-tha)RuCI(en)][PF6J (12) 
were synthesized by Dr. Haimei Chen as described elsewhere. 17 Glutathione (GSH. 
reduced), guanosine 3',5'-cyclic monophosphate (cGMP), sodium salt, disodium 
hydrogen phosphate, and Chelex resin (used for removal of impurity ions from 
phosphates) were purchased from Sigma; sodium dihydrogen phosphate, sodium 
perchlorate, the ruthenium standard for atomic spectrometry (1003 pgRu/rnL ' ) and the 
phosphorus standard for atomic spectrometry (1030 pgP/rnL 1 ) from Aldrich: sodium 
hydroxide and sodium chloride irorn Fisher; trifluoroacetic acid (TFAH) from Acros; 
triethylammonium acetate buffer (TEAA) and ammonium acetate (AA) from Fluka, and the 
aqua solutions of two 14-mer DNA oligonucleotides (sequences as shown below), which 
are HPLC purified Na salts (E 260 nin = 149.8 LmmoFcm' for I, 6 260 nm = 139.4 
L.mmolLcm l for II), were purchased from DNA Technology A/S. 
A l T2 A3 C4 A5 T6 G7 G8 T9 A10 C11 A l2 T13 A14 	(I) 
T28 A27 T26 G25 T24 A23 C22 C 1 AN  T19 G18 T17 A16 T15 	(II) 
4.2.2 Methods 
4.2.2.1 High Performance Liquid Chromatography (HPLC) 
For DNA oligonucleotide work, HPLC separations were carried out on a PLRP-s 
reversed-phase column (250 mm x  4.6 mm, 300 A, 5 pm., Polymer Labs) with detection 
at 260 nm. Mobile phase A: water (for HPLC application, Fisher Chemicals) containing 
20 mM TEAA; mobile phase B: acetonitrile (for lIPLC application, Fisher Chemicals) 
containing 20 mM TEAA. The flow rate was 1.0 niL mm '. The gradient (solvent B) was 
as follows: 11.5% to 80% within 16 mm, reset to 11.5% within I nun, and kept at 11 .5% 
from I7to22min. 
4.2.2.2 Nanoscale Liquid Chromatography Fourier Transform Ion 
Cyclotron Mass Spectrometry (Operated by Mr. Stefan Weidt) 
Negative-ion electrospray ionization mass spectra were obtained with a Bruker APEX 
III ESI-FT-ICR mass spectrometer (Bruker Daltonics, USA) equipped with a 9.4 T 
superconducting magnet (Magnes, UK). An UltiMate 3000 series system (Diones, UK), 
with a nanoflow splitter, was coupled to the mass spectrometer using an TriVersaTM 
NanoMate® (Advion, USA) with spray voltage set to 1.7 W. Mobile phase: water (for 
LC-MS application, Fisher Chemicals) containing 20 mM AA. The sample was eluted 
onto a TSK-Gel® Super SW2000 column (4.6 mm ID x  30 cm, 4 ltm) with a 
guardcolumn (4.6 mm x  3.5 cm). The flow rate was 300 nL min'. A modified heated 
metal capillary was used with temperature set to 423 K held at a potential of 50 V. All 
Spectra were acquired using Wass 7.02 (Bruker Daltonics) with 512 k datapoints in the 
range 90 to 3000 m/z. Bruker Daltonics Data Analysis software was used for analysis 
and postprocessing. 
4.2.3 Preparation of Samples 
4.2.3.1 Preparation of the 14-mer DNA duplex 
The 14-mer DNA duplex III (Scheme 4.1) was prepared by mixing the single-stranded 
DNA oligonucleotide 1 (0.5 mM) with the complementary single-stranded DNA 
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oligonucleotide 11(0.5 mM) in NaC104 (100 mM) to maintain duplex stability in a 10 
mm path length quartz cuvette, and the solution was incubated in a temperature 
controller at 288 K at the beginning. Then the temperature was increased from 288 K to 
353 K within 2 mm, and finally decreased from 353 K to 288 K within 3 h. The presence 
of duplex Ill was confirmed by 'H NMR. 
Scheme 4.1 Preparation of III. 
A1 T2 A3 C4 A5  T'6 G7 G8 T9 A10 C11 A l2 T13  A N 	(I) 
T28 A27 T26 G25 T24 A23 C22 C, A20 T19 G18 T17 A16 T15 	(II) 
1+11=111 
4.2.3.2 HPLC 
Reaction mixtures of complex 1 with GSH and cGMP at various molar ratios under 
physiologically relevant conditions (phosphate buffer pH 7.0, 22 mM NaCl) were 
prepared by mixing aliquots of 10 mM 1, 50-500 mM GSH, and 20-100 mM cGMP, and 
the pH values of all starting solutions were adjusted to 7 using NaOH and HCI04, and 
the 02 content was minimized by bubbling with N2 before and after mixing unless 
otherwise stated. The mixtures were diluted to the required concentration with deionized 
water or with 10-50 mM phosphate buffer solution (pH 7.0, purged with N2), bubbled 
with N2 again, and then incubated at 310 K in a water bath for the required times for the 
subsequent HPLC and LC-MS analysis or preparative separation. The reaction mixtures 
of complexes 1 or 12 with GSH and DNA oligonucleotides at different molar ratios 
under physiologically-relevant conditions (TEAA buffer, pH 7.0, 4 mM NaCl) were 
prepared by mixing aliquots of 1 mM 1 or 12, 50 mM GSH and 0.5-1 mM DNA 
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oligonucleotides, and the pH value of GSH solution was adjusted to 7 using NaOH and 
HCI04. All the reactions were carried out in the presence of air. 
The time-courses of reactions of 1 (20 pM) with GSH (5 mM) and cGMP (0.5 mM) 
under N2 (all starting solutions purged by N2 bubbling) at 310 K were followed 
chromatographically by injection of aliquots of the mixtures onto the HPLC column at 
various time intervals. Sampling at various times was done in air by briefly removing the 
lid to extract an aliquot with no further N2 bubbling. 
4.2.3.3 NMR 
A 10 mM solution of ' N-labeled complex 1 ( '5N-1) was used to follow reactions of 1 
with GSH and cGMP by ID [1H]  and 2D [' l-1,1 N] I-ISQC NMR. The reaction mixtures 
were prepared using the same method as that for 11PLC samples. 
4.2.3.4 Determination of Extinction Coefficients 
HPLC fraction of cGMP adducts were collected from 30-h reaction mixture of complex 
I with GSH and cGMP in buffer. The value of Relative Extinction Coefficients at 254 
nm for [(16-bip)Ru(en)(cGMP-N7)](13) is 2.62 (8{(I16 hjp)IU(efl)CtI± (1)'  
4.2.3.5 Measurement of DNA oligonucleotides concentrations 
The aqueous solution of two 14-mer DNA oligonucleotides (I and II) was diluted in 5 
mL deionized water for P determination by ICP-OES, using a Perkin-Elmer Optima 
5300 DV Optical Emission Spectrometer equipped with an AS-93plus autosampler and 
WinLab32 for ICP program (version 3.0.0.0103). The concentrations of the DNA 
oligonucleotides were calculated using eq 3. and the values are listed in Table 4.1. 
[DNA oIig.] (mM) = [P] (mg/L) x  fold (diluted) / (31 >< 13) 	(3) 
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where 13 arises from the 13 phosphates in both of the DNA oligonucleotides, 
respectively, 31 is the molecular weight of the P atom. 
Table 4.1 Concentrations of 14-mer DNA oligonucleotides purchased from DNA Technology 
A/S. 
P 	I 	DNA olig. 
DNA oligonucleotides I 	/mg mL' 	I /mM 
1 	 3.063 	1.510 
II 	 3.845 	1.793 
4.3 Results and Discussion 
4.3.1 Competitive Reactions of GSH and cGMP with Complex! under 
physiologically relevant conditions 
The competitive binding of cGMP and GSH to complex 1 was investigated. Incubation 
of 20 pM 1 with 250 mol equiv of GSH and 25 mol equiv of cGMP in phosphate buffer 
(pH 7) containing 22 mM NaCl at 310 K for 30 h gave rise to both GSH-and cGMP 
containing products (Figure 4.2). All initial solutions at neutral pH were purged with N2 
before and after mixing to minimize their 02 content. HPLC fractions a and b (Figure 
4.2) contained the thiolato adduct 4 and sulfenato adduct 10, respectively. The mass 
spectrum of fraction c (Figure 4.3) contained a singly-charged ion peak at m/z 774.2 and 
a doubly-charged ion peak at m/z 659.9, assignable to the TFA ion-paired adduct of the 
cGMP complex [(rl 6-bip)Ru(en)(cGMP)] [TFA] (calcd m/z 774.1 for { 
bip)Ru(en)(cGMP)][TFA] + H}
+




 (calcd m/z 
660.1), respectively, confirming the formation of the cGMP adduct [16-bip)Ru(en)- 
(cGMP)f(13).  After 30 h of reaction, the ratios of 4:10:13 were 18:15:13. The presence 
of N7-bound cGMP in 13 was confirmed by the 'H NMR time course of a 24-h reaction 
mixture of 1 mM 1 with 5 mM GSH and 1 mM cGMP, which showed a peak at b 8.28 
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Figure 4.2 HPLC chromatograms for reactions of 1 (20 duM)  with 250 mol equiv GSH 
(bottom), and with 250 mol equiv GSH and 25 mol equiv cGMP (top) in phosphate buffer (pH 
7) containing 22 mM NaCl at 310 K for 30 h. Peak assignments: (a) thiolato adduct 4; (b) 
sulfenato adduct 10; (c) cGMP adduct 13. The nucleotide adduct is still formed even in the 
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Figure 4.3 Mass spectrum for HPLC fraction m from the reaction of complex 1 with GSH and 
cGMP (1: 10 : 25 mM) in phosphate buffer (pH 7.0) containing 22 mM NaCl at 310 K for 30 h, 
showing the detection of the cGMP adduct [(116-bip)Ru(en)(cGMP-N7)] (13) (calc m/z 660.1 
and 774.1 for {[(1 6-bip)Ru(en)(cGMP)]2}2 and {[( 6-bip)Ru(en)(cGMP)][TFA] + H}, 
respectively). The TFA anion is from the ion-pairing reagent TFAH used in the HPLC 
separation. 
A similar reaction mixture was prepared and sampled in air at various time intervals 
over 3 d for HPLC assays (Figure 4.4). In this case, conversion of the thiolato adduct 4 
to the sulfenato complex 10 began after only 6 h, and by 24 h all the thiolato adduct had 
disappeared. After 72 h, the major product (ca. 62% of the total Ru) was the cGMP 
adduct 13 (Figure 4.4). 
cGMP (25 rnol equiv) was added to a solution of 1 (20 1uM) which had been allowed to 
react with 250 mol equiv GSFI for 6 h at 310 K. After 24 h, the cGMP product 13 
accounted for 12% of the Ru present. the thiolato adduct 4, 49%, and sulfenato adduct 
10, 34% (Figure 4.5). Addition of only 5 mol equiv of cGMP to a similar solution of 20 
pM 1. which had reacted with 250 mol equiv of GSH for 6 h. still gave rise to a 
detectable amount (5%) of the cGMP product 13 after 24 h (Figure 4.5). 
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Figure 4.1 (A) HPLC time-course for the competitive reaction of! (20 ,UM) with 250 mol equiv 
of GSH and 25 mol equiv of cGMP in phosphate buffer (pH 7) containing 22 mM NaCl at 310 
K. Peak assignments: (d) [(1 
16 	 2+ 
-bip)Ru(en)(H20)] (2); (a) thiolato adduct [(ri
6 
 -bip)Ru(en)(GS)] 
(4); (b) sulfenato adduct [(1 
16 




 (13). (B) 
Variation of the relative Ru concentrations of species detected during the reaction in (A) with 
time (processed by Dr. Fuyi Wang). The HPLC areas were calibrated by ICP-OES; the relative 
extinction coefficients for complexes 2, 4, 10, and 13 are listed in Table 5.1. The thiolato adduct 
appears to be converted to the sulfenato adduct after 6 h that, in turn, appears to be converted to 
the cGMP adduct after 24 h. Some formation of 13 by direct reaction of cGMP with 2 may also 
occur. 
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Thiolate adduct 4 
sulfenato adduct 10 	I 
adiduct 13 
b 	a 
10 	 20 
Retention Time I mm 
Figure 4.2 HPLC chromatograms for the 24-h reaction mixtures of (A) 0.5 mM and (B) 0.1 
mM cGMP with 20 ltM complex 1 which had first reacted with 5 mM GSH for 6 h at 310 K. 
The competitive reaction of GSH and cGMP at millimolar concentrations 
(i:GSH:cGMP 1:5:1 mM) was also followed by 2D [1 H,15N] HSQC NMR at 310 K 
15 	 15 	
i 	
I 	15 
using N-labeled 1 ( N-i). The spectra are shown n Figure 4.6 and the H and N 
NMR chemical shifts are listed in Table 4.2. During the early stages (<1 h), a pair of 
new cross-peaks (4a, 4b) was observed for the 15N-en ligand in thiolato adduct 4, and 
after 2 h, cross-peak 13a appeared, assignable to the cGMP adduct [( 6-bip)Ru-(15N-
en)(cGMP)f (13). This increased in intensity until 72 h. After 12 h, two pairs of cross-
peaks (lOaIb and IOc/d) were detectable and can be assigned to the sulfenato complex 
[( 6-bip)Ru(15N-en)(S(0)G)] (10) in accordance with the HPLC results (Figure 4.4). 
Cross-peaks 4a!b and lOa/b/c/d slowly decreased in intensity after Ca. 50 h. It is notable 
that a pair of cross-peaks (14a!b) assignable to the phosphate adduct [(16-bip)Ru(
1 
5N-
en)-(PO4)] (i4)[681  is observed for the equilibrium solution of complex I in 50 mM 
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phosphate buffer (pH 7). After Ca. 36 Ii, cross-peak ISa corresponding to the release of 
5 
N-en from gi utath i one-coordinated RU complexes appeared. 
Table 4.2 'H, '5N NMR peaks observed for reactions of '5N-1 (1 mM) with GSH (5 mM) and 
cGMP (1 mM) in 50 mM phosphate buffer (pH 7) and 22 mM NaCl (Figure 4.6) at 310 K. 
complex 	 (peak)ö IH/15N 
1 	 (la) 6.09/-24.62 
	
(I b) 4.05/-24.62 
2 	 (2a)5.64/-19.50 
	
(2b) 4.491-19.50 
4 	 (4a) 5.68/-27.74 
	
(4b) 3.60/-27.74 
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Figure 4.3 2D [1H, '5N] HSQC NMR time course for the reaction of 
'5N-1 0 mM) with GSFI 
(5 mM) and cGMP (1 mM) in 90% H20 I 10% D
20 over a period of 72 h. Assignments: la/b 
complex 1 (li6 bip)Ru(l5Nen)C1i, 2aTh complex 2 
ftfl6 bip)Ru(15Ne11)(H20)12 , 4a/b thiolato 
adduct 4 [(16 bip)Ru('5N-en)(GS)1 I Oa/b and 1 Odd sulfenato adduct 
10 [( 6 bjp)Ru(l5N 
en)(S(0)G)], 13a cGMP product 13 [(ll6 bip)Ru(15
Nen)(cGMP)1. As for the guanosine 
complex [(6bip)Ru(15Nefl)(GU0N7)1 (Chen, H.; Parkinson, J. A.; Parsons, S.; Coxall, R. A.; 
Gould, R. 0.; Sadler, P. J. J. Am. Chem. Soc., 2002, 124, 
3064), resonances for the en NHâ 
protons of 13, which are oriented away from the biphenyl ligand, are too broad to observe. One 
set of cross-peaks (14aJb) corresponds to 15
N-en in the phosphate adduct 14, [(16bip)Ru(N 
en)(PO4-O)f. Note the appearance of cross-peak ISa after ca. 36 h, assignable to 
'5N-en, and 
indicative of some release of en. The non-equivalence of the nitrogens and the protons of the 
15
N-en ligand in 10 is also evident, perhaps strongly influenced by the adjacent chiral S atom. 
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Previous work in our laboratory has shown that en RU 
11 
 arene complexes exhibit a high 
selectivity for N7 of guanine in reactions with DNA 
(1-7c] 
 and show little binding to the 
6 
phosphate group of diesters. 
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 The en NH, protons in [(q-arene)Ru(en)Cl]
+ 
 can form a 
strong 1-1-bond with the exocyclic C6 carbonyl oxygen of G but are repulsive toward 
exocyclic amino groups of nucleohases, and this appears to contribute to the high base-
selectivity. Arene ligands which contain an extended )'-electron system. as in the 
biphenyl group of 1, can provide additional stabilization for the interaction between the 
Ru"  arene complexes and nucleosides or nucleotides by hydrophobic it-it stacking with 




No peaks with N-en chemical shifts similar to those of 0-hound adducts
6 
 [(rl - 
bip)Ru(en)(GS-0)] (Chapter 3) were observed, again suggesting that 10 contains an S-
bound sulfenate. In the process of oxidation of thiolate, sulfenate can he further oxidized 
to sulfinate.19 ' However, in the reaction of I with (iSIl with cGMP at p11 7, the oxidized 
thiolate remains as sulfenate due to the presence of GSH which acted as reductant and 
the —S(0)G was substituted by cGMP before it was further oxidized to —S(02)G. 
The sulfenato complex 10 was protonated at pH Ca. 21101  to form sulfenic acid 
bip)Ru(en)(S(OH)G-,S')]+ (15) which is very highly reactive. 1 Even at pH 7, a small 
amount of sufenate 10 was protonated to form the sulfenic acid which appeared to be 
readily displaced by cGMP giving the cGMP adduct 13 [(i16-bip)Ru(en)(cGMP-N7)] as 
the dominant product of the reaction (Figure 4.4. Scheme 4.2). This implies that the 
sulfenato ligand is readily substituted by cGMP, but the thiolato ligand is not. Cisplatin 
and related pt"  anticancer complexes can catalyze the breaking of disulfide bonds, '1 but 
thiolates bound to Pt"  are not readily displaced by N7-donor ligands, guanine or 
	
14c 21 	 4bcj 
adenine. 	However. S-donor thioether ligands such as L-methionine 	and S- 
methylated glutathione (GSMe)1431  bound to P1U  are readily substituted by N7-donor 
nucleosides or nucleotides and oligonucleotides. On the other hand, GSH facilitates the 
binding of [Ru
UI 
 Cl(NH3 2+ 
	 U 
)5] to DNA through reduction to [Ru (H20)(NH3)51 
2+ 
III 
However,  at [GSH]/[Ru] > 1. GSH inhibits the binding of [Ru CI(NH3 )51 to DNA by 
111 
2+ 
forming [Ru (GS)(NH 3)51 , and a high [GSH]/[Ru] even eliminates G N7 
coordination. 161 But in the competition between GSH and cGMP for Ru(II) arene 
6 	 + 	 . 
complex [(i' -bip)Ru(en)Cl] , GSH can not block the binding 011 to cGMP even in the 
presence of excess GSH (Figure 4.4 and 4.6) due to the formations of sulfenato adduct 
10 and the sulfenic acid which appear to provide a facile route for displacement of S-
bound glutathione by G N7. 
Scheme 4.2 Pathway for reaction of complex I with cGMP and GSH at pH 7. 










(( 6-bip)Ru(en)(GS(OH)-S)] (15) 
unstable 
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4.3.2 Competition between GSH and DNA oligonucleotides for Ru(II) 
Arene Anticancer Complexes under physiologically-relevant 
conditions 
4.3.2.1 Competitive reaction of complex 1 with GSH and single strand II 
Reactions of 1, GSH (pH 7) and single strand II in different ratios, incubated under 
physiologically-relevant condition (pH 7, 4 mM NaCl) for 48 h, gave rise to one 
monoruthenated oligonuleotide product, as separated and identified by HPLC-ESI-MS 
(Figures 4.7 and 4.8). The fraction e (Figure 4.7) corresponds to the mass spectrum (B), 
in which the triply-charged ion peak centred at m/z 1416.7 and the quadruply-charged 
ion peak centred at m/z 1062.4 (Figure 4.8(B)) were both assigned to free single strand 
II according to the simulation (Figure 4.8(D)). FSI-MS analysis of the HPLC fraction f 
(Figure 4.7) gave one triply-charged ion peak centred at m/z 1521.3 and one quadruply-
charged ion peak centred at m/z 1140.9 (Figure 4.8(A)), both assignable to 
monoruthenated single strand II adduct 16 on the basis of the simulation (Figure 4.8(C)). 
No ruthenated GSH product was detected, which indicated that the Ru complexes are 
not inactivated by GSH. Similar result was obtained in the competitive reaction of 1 with 
histidine and II at pH 7, in which no histidine adducts of complex 1 were formed in the 
presence of the oligonucleotideJ141 In this reaction, G18 and G25 are two potential 
targets, but specific assignment of monoruthenation site to G18 or G25 was not made. '51  
For the reactions of 1 and duplex III, the NMR studies identified five mono-ruthenated 
oligonucleotides (two conformers were identified for the G 1 8-ruthenated adducts), 





0: 0: 0.1 mM 
0.1:1:0.1mM 
0.1: 1: 0.2 mM 
0.1: 5 : 0.1 mM 
0.1 : 5: 0.2 mM 
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Retention Time I mm 
Figure 4.4 HPLC separations for reactions of 1, GSH and single strand II in different ratios 
(as shown above) at 310 K for 481i. 
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Figure 4.5 	(A) ESI mass spectrum for HPLC fraction e (Figure 4.7); (B) ESI mass spectrum 
for HPLC fraction f(Figure 4.7); (C) Simulation for species f which is a monoruthenated single 
strand II adduct 16; (D) Simulation for species e which is free single strand II. 
4.3.2.2 Competition of 1 with GSH and 14-mer duplex 
The 14-mer duplex III was prepared from the two single strands I and II (I + II = III; 
Scheme 4.1), and the annealing was confirmed by NMR (Figure 4.9). The pattern of tH 
chemical shifts for the imino region arising from hydrogen bonds forming of duplex III 
was similar to that shown in the literature ('H chemical shifts are listed in Table 43)•[t61 
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Products from reactions of 1(0.1 mM) and duplex III (0.1 mM) with GSH (1 mM, pH 
7) and without GSH for 48 h, were separated and analysed by conventional LC-ESI-MS 
(Figure 4.10 and 4.11). The HPLC assays gave identical chromatograms (Figure 4.10) 
for the two reaction mixtures, but the MS analysis of the fractions (Figure 4.11) was not 
able to give unambiguous identifications for the ruthenated duplex III products due to 
the low resolution. Therefore, nano-HPLC-FT-ICR-MS was applied to analyse the 
reaction mixture in the presence of GSH. A series of triply-charged and penta-charged 
ion peaks was detected for the fraction eluting from 4 to 6 mm (Figure 4.10). The ion 
peaks centred at m/z 1416.2 and 1422.2 (Figure 4.12(A)) were assigned to free single 
strand II and I, respectively, due to the fragmentation of duplex III during the 
ionisation, and the two ion peaks centred at m/z 1521.3 and 1527.3 (Figure 4.12(A)) 
were assignable to mono-ruthenated single strand II and I adducts 16 and 17, 
respectively. The two penta-charged ion peaks centred at m/z 1703.4 and 1766.2 are 
assignable to free duplex III and mono-ruthenated duplex III adduct 18 (Figure 
4.12(B)), respectively. When the molar ratio of Ru:III:GSH was changed to 2:1:20 
(0.1:0.05:1 mM), besides the mono-ruthenated duplex III adduct 18, a di-ruthenated 
duplex III adduct 19 was identified by nano-HPLC-FT-ICR-MS (Figure 4.13 and 4.14) 
for the reaction mixture incubated for 48 h. Interestingly, two ruthenium glutathione 
complexes were detected by conventional LC-MS (Figure 4.15 and 4.16) for the reaction 
mixture of 1 (0.1 mM), GSH (5 mM) and duplex III (0.05 mM) incubated for 16 h. The 
ion peak centred at m/z 562.45 corresponds to a mono-ruthenated glutathione adduct 4 
[( 6-bip)Ru(en)(SG)], and the other ion peak centred at m/z 638.02 is assignable to a 
mono-ruthenated glutathione sulfenate adduct 10 [(16-bip)Ru(en)(SOG)], which 
indicates that the pathway for competitive reaction of 1 with GSH and DNA 
oligonucleotides (Scheme 4.3) is similar to that for reaction of 1 with GSH and cGMP 
(Scheme 4.2). Therefore, in the reaction of 1 with duplex III, sulfenato complex 10 
plays the same role as that in the reaction of 1 with cGMP. 
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Figure 4.6 (A) The imino region of the 'H NMR spectrum of III obtained at 288 K. (B) The 
same region of 'H NMR spectrum of III at 278 K as published previously in the literature." 
(C) The chemical structures and numbering for the guanine and thymine bases. 
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Table 4.3 	'H chemical shift assignments (ppm) observed for the imino region of duplex III 
compared to published values. [161 
Base' 	GH1/TH3' I GH1/TH3 (1111) 
T6 13.54 
G7 12.52 12.55 
G8 12.64 12.69 
T17 13.31 13.40 
G18 12.38 12.42 
T19 -c 13.48 
T24 -c 13.51 
G25 12.32 12.37 
T26 	1 13.31 	I 	13.40 
'The numbering for duplex III is shown in Scheme 5.1; b  The numbering is shown in Figure 
6.9(C); C  The signals are weak and the three peaks are overlapped. 
(A) 
0 	 5 	 10 	 15 	 20 
Retention Time I mm 
Figure 4.7 (A) HPLC separation for the reaction of 1 (0.1 mM) and I 4-mer duplex III (0.1 
mM) under physiologically-relevant conditions for 48 h; 	(B) HPLC chromatogram for the 
reaction of 1(0.1 mM), GSH (1 mM) and 14-mer duplex III (0.1 mM) under physiologically-
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Figure 4.8 (A) ESI mass spectrum for the fraction g (Figure 4. 0); (B) ESI mass spectrum of 
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Figure 4.9 FT-ICR mass spectra for the fraction eluting from 4 to 6 mm (Figure 4.10). 
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Figure 4.10 Nano HPLC separation for the reaction mixture of! (0.! mM) with GSH (1 mM, 
pH 7) and duplex III (0.05 mM) after incubation for 48 h. 
[11+ 1 OH]3- 
14 16.2 
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Figure 4.11 FT-ICR mass spectra for the fraction eluting from 9 to 10 mm (Figure 4.13). 
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Figure 4.12 	HPLC separation for the reaction of 1(0.1 mM) with GSH (5 mM, p1-I 7) and 
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Figure 4.13 	(A) ESI mass spectrum for the fractions eluting from 10.4 to 11 mm (Figure 
4.15); (B) ESI mass spectrum for the fractions eluting from 7.5 to 10 mm (Figure 4.15). 
122 




DNA oligo, Ill duplex Ill 
((q6-bip)Ru(en)(GS-S)] (4) 
[(q6-bip)Ru(en)II]11- (16) 
02 	 [( 6-bip)Ru(en)Ill]24- (18) 
[(q6-bip)Ru(en)(GS(0)-S)] (10) 	 C[(r16-bip)Ru(en)12111}22- (19) 
Z+ DNA oligonucIeotide Ill duplex Ill 
[( 6-bip)Ru(en)(GS(OH)-S)] (15) 
highly reactive 
4.3.2.3 Competitive reaction of complex 12 with GSH and 14-mer duplex 
Reaction mixtures of 12 (0.1 mM) and duplex III (0.1 mM) with or without GSH (I 
mM, pH 7) for 48 h, were separated by HPLC. For each mixture, the separations (Figure 
4.17) gave rise to two fractions which eluted at the same time. A series of triply-charged 
and penta-charged ion peaks were detected for the reaction mixtures (Figure 4.18). The 
ion peaks centred at m/z 1416.2 and 1422.2 were assigned to free single strand II and I, 
respectively, due to the fragmentation of duplex III during the ionisation, and the two 
ion peaks centred at m/z 1530.6 and 1536.6 were assignable to mono-ruthenated single 
strand II and I adducts 20 and 21, respectively. The two penta-charged ion peaks centred 
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at m/z 1703.4 and 1778.5 are assignable to free duplex III and mono-ruthenated duplex 
III adduct 22, respectively. 
(B) 
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Retention Time I mm 
Figure 4.14 (A) HPLC separation for the reaction mixture of 12 (0.1 mM) with duplex III (0. 1 
mM) for 48 h; (B) HPLC chromatogram for the reaction mixture of 12 (0.1 mM) with GSH (1 
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Figure 4.15 FT-ICR mass spectrum for the reaction mixture of 12 (0.1 mM) with GSH (1 mM, 
pH 7) and duplex III (0.1 mM) after 48 h. 
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Hydrophobic interactions between the arene ligand in these Ru(II) arene anticancer 
complexes, [(1-l6-arene)Ru(en)C!], and DNA can produce a driving force for DNA 
binding. [171  The most active complexes contain the most hydrophobic 116-arene 
ligands. 17al  Complex 12 was used for comparison with I because the 16-arene ligand in 
12 (tha) is more hydrophobic that that in 1 (bip). The reaction of complex 12 with 
duplex III at the presence of GSH was shown to be similar to the reaction of 1 with III 




Cells contain high (millirnolar) concentrations of the tripeptide glutathione which has 
several binding sites for metal ions: the amino and carboxylate groups at the GIn 
terminus, carboxylate at the Gly terminus, and thiolate sulfur of the central Cys residue. 
Binding to the deprotonated amide nitrogen of Cys is possible when a N/S chelate ring 
118! 
can be formed, as has been observed for platinum amine complexes. 	For heavier, 
'soft" transition metal ions, thiolate sulfur is a particularly strong site, and for Pta, such 
bonds are essentially formed irreversibly. Elevation of GSH levels therefore provides 
cells with detoxification and resistance mechanisms. 3'41 Therefore reactions of the 
ii 	 6 	 + 
organornetallic Ru arene anticancer complex [( -bip)Ru(en)ClJ with GSH and 
cGMP/DNA oligonucleotides were investigated, in particular, whether the presence of a 
large molar excess of GSH (as would be the case in cells) could prevent binding to the 




on DNA. The 
strategy used here involved separation of the products by H1LC and identification by 
ES!-MS, and after preparative HPLC, characterization by NMR spectroscopy. 
labeling of the chelated ethylenediarnine ligand and use of 2D [1 H,15N] HSQC NMR 
spectroscopy was helpful for elucidation of some of the complicated reaction pathways. 
First the competitive reaction of complex I with 250 mol equiv GSH and 25 mol equiv 
cGMP119' under the physiologically relevant conditions (phosphate buffer pH 7, 22 mM 
6 
NaCl. 310 K) was investigated. This gave rise to the cGMP adduct [(ii - 
bip)Ru(en)(cGMP-1V7)] (13) as the major product. accounting for ca. 62% of total RU 
after 72 h (Figure 4.4 and 4.6). This suggests that oxidation of coordinated glutathione in 
the thiolato complex 4 to the sulfenate in 10 and protonation of 10 to sulfenic acid 
provide a facile route for displacement of S-bound glutathione by G N7 (Scheme 4.2). a 
route for RNA and DNA rutlienation even in the presence of a large excess of GSH. 
4-mer DNA oligonucleotides were used for further studies. The reactions of 1 or 12 with 
GSH and DNA oligonucleotides still followed a similar pathway as that for the reaction 
of 1 with GSH and cGMP-giving rise to the DNA adducts 16-22 (see Figure 4.8, 4.12, 
4.14 and 4.18) as final products via the sulfenate adduct 10 (Scheme 4.3). 
This work has revealed unusual redox reactions of cysteinyl adducts of a 
monofunctional ethylenediamine Ru"  arene complex with glutathione, which provides a 
facile route for displacement of S-bound glutathione by G N7 for these Ru(II) arene 
anticancer complexes. In order to do the further studies on sulfenate complexes, a series 
of novel Ru(ll) arene complexes in which SR was used as a leaving group were 
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5.1 Introduction 
"Half-sandwich" Ru(II) arene anticancer complexes were found to have good aqueous 
solubility which is an advantage for clinical use, and the arene ligand can be inert 
towards displacement under physiological conditions."' A typical series of half-
sandwich "piano-stool" Ru(II) arene anticancer complexes is [(11  
in which X is a leaving group providing a potential binding site for nucleotides via 
hydrolysis, and activities of these complexes correlated with the hydrolysis rate of the 
leaving group)1'2' The leaving group X is usually a halide which is hydrolysed to form 
the active aqua complex, [21  and substituted by biological molecules such as guanine 
basesJ3'41 Recently, some novel Ru(II) arene anticancer complexes containing 
different leaving groups, such as SPh and SC3H7 (SR), were synthesized and their 
anticancer activities were studied in our research group. Interestingly, no hydrolysis 
for complex [( 6-hmb)Ru(en)(SPh)]PF6 (23; hmb = hexamethylbenzene) was 
observed, however, it still has relatively high cytotoxicity (1050 = 23 1tM)J5' In 
Chapter 3, it was shown that GSH can be oxidized to GSOH or GS02H which play 
important roles in physiological reactions. [6,71  Furthermore, thiols are considered to 
have one of the most reactive functional groups found in cells, and sulfenic acids 
RSOH are believed to be involved in these biological reactions. 81 These acids have 
been proved as key intermediates in many biochemical reactions. [9, 
In this Chapter, oxidations of complex 23 and another complex [( 6-hmb)Ru(en)(S-
iPr)]I (24; iPr"isopropyl) were studied, and two-step reactions were discovered in 
which formation of final products (sulfinate adducts) occured via sulfenate 
complexes. The reaction of the sulfinate adduct with cGMP under physiologically-
relevant conditions (phosphate buffer, pH 7, 22 mM NaCl) at 310 K, was compared to 
the reaction of 23 with cGMP under the same conditions, and much more 





[(96-hmb)Ru(en)(SPh)]PF6 (23), [( 6-hmb)Ru(en)(S-iPr)]I (24) [(r 6-hmb)Ru('5N-
en)(S-iPr)]I ('5N-24) and were synthesized, purified and characterised as pure 
unoxidised compounds using HPLC, ESI-MS and NMR spectroscopy by Dr. Holm 
Petzold. Glutathione (GSH, reduced), sodium chloride, disodiurn hydrogen phosphate, 
and Chelex resin (used for removal of impurity ions from phosphates) were purchased 
from Sigma; sodium dihydrogen phosphate and the ruthenium standard for atomic 
spectrometry (1003 pgRu/mL 
1) 
 from Aldrich: sodium hydroxide and sodium chloride 
from Fisher; and trifluoroacetic acid (TFAH) from Acros. Hydrogen peroxide (30% 
aqueous solution) was purchased from Prolabo. 
5.2.2 Methods 
5.2.2.1 High Performance Liquid Chromatography (HPLC) 
Columns and mobile phases were same as those described in Chapter 3. The gradient 
(solvent B) was as follows: 10% to 25% within 10 mm, 80% from 15 to 19 mm, reset 
to 10% from 20 to 25 mm. 
5.2.3 Preparation of Samples 
5.2.3.1 UV-Vis 
The reactions of 23 (0.1 mM)/24 (0.1 mM) with H202 (0.6 mM) in unbuffered water 




For all the reaction mixtures containing GSH, before GSH was added, the pH values 
of GSH were adjusted using NaOH and HC104 to ca. pH 7. 
For the reaction of 23 with 02 at 310 K for 24 h, the experiment was set up as shown 
in Figure 5.1. The reaction solution was connected with an oxygen cylinder. Oxygen 
was bubbled into the reaction solution for 24 h, and the flask was incubated in a 
water-bath at 310 K. 
02 
Figure 5.1 The apparatus used for the reaction of 23 with 02 at 310 K for 24 h. 
For ESI-MS samples, HPLC fractions were collected from the 24-h reaction mixture 
of 23 with H202  at various molar ratios in water. After lyophilization. the residue 
from each fraction was re-dissolved in 50% H20/50% CH3CN to the final 
concentration of Ca. 0.05 mM. 
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For NMR samples, the reaction mixture of 23 (1 mM) with H202 (6 mM) in MeOD at 
298 K was recorded by 'H NMR spectroscopy every 2 min for 24 h, and another 
reaction mixture of 24 (2 mM) with GSH (10 mM) and cOMP (4 mM) under 
physiologically-relevant described as above containing 10% D20 at 310 K was 
recorded by ID NMR and 2D ['H.'5N] HSQC NMR spectroscopy every 2 h for 62 h. 
All NMR data were processed using topspin-nmr (version 1.3. Bruker Biospin. Ltd.). 
5.2.3.3 Determination of Extinction Coefficients 
HPLC fractions of complex 23, its sulfinate adducts were collected from a 10 mM 
equilibrium aqueous solution of 23, the 24-h reaction mixture of complex 23 with 
11202 in water, 24-h reaction mixture of complex 23 with cGMP in buffer containing 
22 mM NaCl. The values are listed in Table 5.1. 
Table 5.1 Relative extinction coefficients at 254 nm of HPLC-isolated Ru arene complexes 
Ru" Ru peak 
Complex /pg mL /nmol area  	ER24c 
[(ii-hrnb)Ru(en)(SPh] (23) 1.76 87.1 3621.54 	1.00 
[( 6-hmb)Ru(en)(S01Ph)] (26) 6.04 299 19238.5 	1.55 
a  Ru concentration in 5 mL aqueous sample determined by ICP-OES. 
b  Relative peak areas of HPLC fractions with UV detection at 254 nm. 
Relative extinction coefficient. 
5.3 Results and Discussion 
5.3.1 Oxidation of Pure Complex 23 or 24 to sulfenate/sulfinate 
adducts 
Since the partial oxidation of sulphur in [(TI 	(23) was observed 
in the x-ray crystal structure (data not shown), aqueous solutions of pure complex 23 
(1 mM) containing phosphate buffer (pH 7) and 22 mM NaC1 in air (i.e. not purged 
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with N2) incubated at 310 K, were monitored by 'H NMR (Figure 5.2(A), Table 5.2) 
to test the stability of 23 under the physiologically-relevant conditions. The empirical 
formula for the crystal structure [Ru(en)(C6Me6)(SPh)o 85(SO2Ph)o15]PF6, indicated 
that 15% of SPh was oxidized to sulfinate S02Ph due to the oxidation of starting 
material NaSPh to NaS02Ph during the synthesis process. The 'H NMR spectra 
(Figure 5.2, Table 5.2) illustrated that the aqueous solution of 23 is stable within 
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Figure 5.2 	(A) Phenyl thiolate region of 'H NMR time course for aqueous solution of 
pure complex 23 (1 mM) under physiologically-relevant conditions in air at 310 K The 
assignment for the three signals were listed in Table 5.2; (B) Chemical structure of 23. 
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Table 5.2 	1 H NMR chemical shifts (ö) for the phenyl thiolate of pure complex {(16 
hmb)Ru(en)(SPh)J (23) (pH 7, 22 mM NaCl) in 90% H20/1 0% D20 (3 10 K) 
Sulfenic acids are generally assumed to be only transient intermediates in the 
oxidation of thiols to both disulfides and sulfinic acids (see Scheme 5.1)," due to 
their instability. The main reason why they are very unstable and highly reactive is a 
facile self-condensation reaction to form the corresponding thiosulfinic-S esters 
RS(0)SR (thisulfinates) involving nucleophilic attack by one sulfenic acid sulphur on 
that of the second RSOH. 121 The X-ray crystal structure of Ru(IJ) arene sulfenate 
complex [( 6-p-cymene)Ru(en)(S(0)-iPr)]I (synthesized and crystallized by Dr. Holm 
Petzold; not shown) showed that the bond length of Ru-S(0) (2.3 788(7) A) is shorter 
than that of Ru-S (2.3932(7) A) obtained from the X-ray crystal structure of Ru(IJ) 
arene thiolate complex [(ij 	(not shown). Similar results 
have been obtained in the crystal structures of cis-dithiolate [1,5-bis(2-
mercaptoethyl)- 1,5 -diazacy-clooctanato] nickel (II) and its sulfenato adduct. [13]  
Ruthenium (II) has a high affinity for sulphur-containing molecules. 1141  Therefore, no 
hydrolysis was observed for complex 23J5' 
Scheme 5.1 Oxidation pathways for thiols giving sulfinic acids and disulfides. 
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5.3.1.1 Oxidation of Pure Complex 23 by Molecular Oxygen 
The reaction of pure complex 23 with pure 02 supplied by an oxygen cylinder (the 
vessel is shown in Figure 5.1) for 24 h at 310 K was investigated using HPLC. 
Compared to the chromatogram of complex 23, the chromatogram for the reaction 
mixture of 23 with 02 at 310 K for 24 h showed that the reaction did not give rise to 




23 in 02  at 310 K for 24 h 
11 	13 	15 	17 	19 
Retention Time I mm 
Figure 5.3 HPLC separations for pure complex 23 and the reaction mixture of 
complex 23 with 02 at 310 K for 24 h. Peak assignments: (a) 23. 
5.3.1.2 Reactions with H202 
The reactions of pure 23 (0.1 mM)/pure 24 (0.1 mM) with H202 (0.6 mM) in 
unbuffered water at 298 K were followed by UV-Vis spectroscopy (Figure 5.4 and 
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5.5). Figure 5.4 shows the absorption band at 252 urn decreased in intensity with time 
and disappeared after 6 mm, and a new absorption band appeared at 327 nm and 
increased in intensity for the first 14 min and then decreased in intensity, and another 
new band at 316 nrn appeared. Figure 5.5 shows a similar variation to that in Figure 
5.4. The two curves in Figure 5.6 indicate that the reactions of pure 23 or 24 with 
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Figure 5.4 UV-Vis time course for the reaction of pure 23 (0.1 mM) with H
202  (0.6 mM) in 
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Figure 5.5 UV-Vis time course for the reaction of pure 
ft 6 hmb)Ru(en)(S-iPr)]T (24; 0. 
mM) with H202  (0.6 mM) in unbuffered water at 298 K. 
0.1 mM 23: 0.6 mM H202 298 K 
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Figure 5.6 Variation of the absorption at 327 nm of the UV-Vis curves shown in Figure 5.4 
and 5.5 with time. 
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Hydrogen peroxide produced in the human body by cells of the immune system, was 
used as a mild oxidant for the oxidation of thiolate complexes (23 and 24) giving 
sulfenate adducts which were further oxidized to sulfinate adducts. In the UV-Vis 
spectra, the peaks at 252 nm in Figure 5.4 and at 260 nm in Figure 5.5 are due to 
thiolato complexes 23 and 24, respectively, while those at 327 nm in Figure 6.4 and 
5.5 are due to the sulfenato complexes 25 and 27. A similar change in the UV-Vis 
spectrum during the photooxidation of [Co(III)(en)2(S-cys)]BF4 has been observedJ'51  
Another two bands at 316 nm in Figure 5.4 and at 300 nm in Figure 5.5 are probably 
assignable to the sulfinato adducts. 
Reaction mixtures of pure 23 and H202 at various mole ratios in water at 310 K for 24 
h were prepared for HPLC and MS analysis. HPLC separations (Figure 5.7) showed 
that the reaction of 23 (1 mM) with H202 (ca. 0.5 mM) in water at 310 K for 24 h, 
gave rise to two oxidation adducts (peaks b and c), while the reaction of 23 (1 mM) 
with H202 (2 mM) in water at 310 K for 24 h, only gave rise to one oxidation adduct 
(peak d). ESI mass spectra (Figure 5.8) from HPLC fraction b (see Figure 5.7) gave 
an 	peak at m/z 449.2 which can be assigned to the sulfenato adduct [(11 6_  
hmb)Ru(en)(SOPh)] (25), and an ion peak at m/z 465.4 from HPLC fraction c (see 
Figure 5.7) assignable to the sulfinato adduct [(116-hmb)Ru(en)(S02Ph)] (26). 
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Figure 5.7 HPLC separations for reaction mixtures of 23 and H202 at various mole ratios (as 
indicated in the Figure) in water at 310 K for 24 Ii. Peak assignments: (a) complex 1; (b) 
6 sulfenato 	adduct 	ftrj -hrnb)Ru(en)(SOPh)]+ 	 6 (25); 	(c) 	sulfinato 	adduct 	[(Ti - 
hmb)Ru(en)(S02 Ph)] (26). 
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Figure 5.8 ESI mass spectra for HPLC fractions (shown in Figure 5.7) collected from the 
reaction of 23 (1 mM) and H207 (0.5 mM) in water at 310 K for 24 h. 
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The reaction of 1 (1 mM) with H202 (6 mM) in MeOD at 298 K was followed by 'H 
NMR spectroscopy (see Figure 5.9(A), Table 5.3). The three blue resonances assigned 
to phenyl thiolate in 23 (blue in Figure 5.9(A)), decreased in intensity and disappeared 
at after ca. 20 mm; meanwhile after ca. 8 min a new adduct [(r 6-hmb)Ru(en)(SOPh)] 
(25) (three new resonances coloured in red in Figure 5.9(A)) formed and increased in 
concentration until 20 mm, and decreased in concentration, then disappeared after ca. 
24 h. Another two new signals labelled in pink appeared, assignable to sulfinate 
adduct [(16-hmb)Ru(en)(SO2Ph)f (26), and increased in intensity with time. Figure 
5.9(B) illustrated that the reaction of 23 with H202 is a two-step reaction, in which 23 
is oxidized to the sulfenate adduct 25, and then 25 is further oxidized to sulfinate 
product 26. It is evident that the reaction rate for the oxidation of 23 to 25 is much 
faster than that for the further oxidation of 25 to 26. 
Table 5.3 	'H NMR chemical shifts for phenyl group in complex 23, adducts [(16W 
hmb)Ru(en)(SOPh)] (25) and [(116-hmb)Ru(en)(SO2Ph)F (26) in MeOD at 298 K (see Figure 
5.9(A)). The labels for the protons are given in Figure 5.2(B). 
Complexes 
Proton 	
23 	 25 	 26 
ö/ppm 
Ho 	 7.24 	 7.29 	 7.67 
Ho' 	 7.24 	 7.29 	 7.67 
Hm 	 7.13 	 7.52 	 7.62 
Hm' 	 7.13 	 7.52 	 7.62 
Hp 	 7.06 	 7.38 	 7.62 
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Figure 5.9 (A) Phenyl region of 'H NMR time course for the reaction of 23 (1 mM) with 
H202  (6 mM) in MeOD at 298 K. There are three sets of signals, assignable to complex 23, 
sulfenate adduct 25 and sulfinate adduct 26, respectively; (B) Variation of the relative Ru 
concentrations of species detected during the reaction in (A) with time. 
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It has been demonstrated that in the absence of metal ions, a two-step bimolecular 
nucleophilic substitution mechanism is involved in thiol oxidation by hydrogen 
peroxide in aqueous solution, in which the rate-determining formation of a reactive 
sulfenic acid intermediate (RSOH) is followed by reaction with a second thiolate to 
form a disulfide (RSSR), the only final product observed in aqueous solutions. 161 In 
the presence of Ru(II), both of sulfenato adduct 25 and sulfinato product 26 were 
observed in the reaction of 23 with H202 at the molar ratio of 2:1 in aqueous solution 
at 310 K for 24 h. Even at the high ratio of H202:23 (6:1), the sulfinato adduct 26 is 
the only product observed in the aqueous solution. According to Figure 5.9(B), the 
formation of the sulfenato adduct 25 is very fast (complete within 20 mm), and further 
oxidation to the sulfinato adduct 26 is much slower (complete within 24 h) which is 
the rate-determining step. Such a reaction pathway has also been observed for the 
reaction of [Co(III)(en)2(S-cys)]BF4 with singlet oxygen. [151 
5.3.1.3 Oxidation of Complex 24 to Sulfenate by Air in Presence of GSH 
The reaction solutions of '5N-24 (1 mM) with or without GSH (10 mM) at pH 7 
containing 22 mM NaCl, were bubbled with air and incubated in water-bath at 310 K 
for 4 h, and then analysed by 2D ['H,'5N] HSQC NMR. One pair of cross-peaks 24a1b 
in Figure 5.10(A) was assigned to [( 6-hmb)Ru(15N-en)(S-iPr)] ('5N-24), and two 
pairs of cross-peaks 27a!b and 27c/d in Figure 5.10(B) are assignable to [(16.. 
hmb)Ru(15N-en)(SO-iPr)f' ('5N-27). The reaction of ' 5N-24 (1 mM) with H202 (6 
mM) at pH 7 (22 mM NaCl) at 310 K for 6 h was monitored by 2D ['H,'5N] HSQC 
NMR (data not shown) and used as basis for the assignment of complex 27. The two 
results (Figure 5.10(A) and (B)) demonstrated that complex 24 can be readily 
oxidized to sulfenato adduct 27 by bubbling with air only in the presence of GSH, and 
GSH/02 acts as oxidant. 
144 








5.0 	4.0 	3.0 	2.0 
8 (1H)Ippm 
Figure 5.10 	(A) 2D [IH,uN] HSQC NMR spectrum for the reaction of 
15N-24 (1 mM) 
bubbled with air at 310 K for 4 h without GSH. Assignment: 24a1b [(6hmb)Ru(  15Nen)(S 
iPr)] ('5N-24); 	(B) 2D [5 H,'5N] HSQC NMR spectrum for the reaction of '
5N-24 (1 mM) 
bubbled with air at 310 K for 4 h in presence of GSH (10 mM). Assignment: 27a1b and 27c/d 
KTI 	("N-27). 
It was demonstrated that the highest rate for air oxidation of GSH to GSSG is at pH 
ca. 9[171 It is believed that in the HL2  form of glutathione (Figure 5
.11),1151 two groups 
(the protonated NH3  and the deprotonated S) interact with each other, at the average 
S-N distance of ca. 2.85 A which is such that a molecule of dioxygen can be easily 
accommodated and activated. '71  However, the mechanism for the oxidation of GSH to 
GSSG are not known, still one supposed mechanism is given in Scheme 5.2. The 
thiolato complex 24 can only be oxidized to the sulfenato adduct 27 in presence of 
GSH by bubbling with Air (Figure 5.10), indicating GSH was involved in this 
oxidation reaction to accommodate 02, and the supposed mechanism for this reaction 
is shown in Scheme 5.3. The excess of GSH was oxidized to GSSG which cannot 
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Figure 5.11 The HL 2- form of glutathioneJ'8' 
Scheme 5.2 Supposed mechanism for air oxidation of GSH to GSSG. 
GSH +02 	 ON. 	[GSOOH] 
1+GSH 
4 GSSG +2 H20 	
+2GSH_ 	
2 GSOH 
Scheme 5.3 Supposed mechanism for the reaction of 2 bubbled with air at pH 7 containing 
22 mM NaCl in presence of GSH at 310 K for 4 h. 
GSH +02 -' 	 [GSOOH] 
+ [(q6-hmb)Ru(en)(S-iPr)] + GSH 
[(q6-hmb)Ru(en)(S(0)-iPr)] + GSSG + H20 
5.3.2 Hydrolysis and Acidity of Sulfenato Adduct 27 
When the HPLC fraction b (see Figure 5.7) was collected for lyophilization, the 
sulfenato adduct 25 was found to have decomposed ('H NMR obtained by Dr. Holm 
Petzold) due to the presence of trifluoroacetic acid (TFA) in HPLC mobile phase 
solvents (pH value ca. 2). Therefore, at low pH values, sulfenato complexes are 
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protonated to give sulfenic acid complexes which are unstable and highly reactive, 8 
as shown in Scheme 5.4. 
Scheme 5.4 Protonation of sulfenate complexes. 
+ 	OH 
I® 	H I M-S-R M-S-R 
+ 
The pKa*  value (pKa value determined for D20 solutions) of the sulfenato complex 27 
was determined by Dr. Holm Petzold using NMR spectroscopy, which is the first time 
to be studied. The change in the 'H NMR chemical shift of the CH proton in 
—S(0)CHMe2 in 27, [(ri6-hmb)Ru(en)(S(0)-iPr)], which predominates in equilibrium 
solution of 27 in D20 at 298 K, was followed with changes in pH*  (pH meter reading 
without correction for effects of D on glass electrode) over the range of 1.50-8.00 
(Figure 5.12). The data were fitted to the Henderson-Hasselbaich equation which 
yielded a pKa*  value of 3.44 for 27 (Figure 5.12). 
Also the hydrolysis of sulfenato complex 27 in 90% D20/10% H20 at 310 K was 
studied by Dr. Holm Petzold using 2D ['H,'5N] HSQC NMR spectroscopy. The 15N-
labelled sulfenato complex ('5N-27) is relatively stable at pH*  7 (phosphate buffer) as 
shown in Figure 5.13(A), and at 16 h after HC1 was added to change the pH  value 
from 7 to 2.11, two pairs of cross-peaks (27a1b and 27c/d) assignable to 
hmb)Ru('5N-en)(S(0)-iPr)] ('5N-27), had disappeared, and another two new pairs of 
cross-peaks (28a1b and 29a/b) were obtained, which can be assigned to 
hmb)Ru('5N-en)Cl] ('5N-28) for 28a!b and [( 6-hmb)Ru(15N-en)OH2]2 ('5N-29) for 
29a/b, respectively (see Figure 5.13(B)) on the basis of the assignments for the 
hydrolysis of complex '5N-28 (Figure 5.13(C)). However, the rate of hydrolysis for 27 







Scheme 5.5. The Ru-S(0) bond becomes weaker at low pH (Ca. 2) due to the 
protonation of sulfenato complex 27. 
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pH 
Figure 5.12 Plot of the 'H NMR chemical shift versus pH at 298 K for —S(0)CHMe
2 
proton of [(l6 hmb)Ru(en)(S(0)iPr)]± (27) in D20. The curve represents the best fit to the 
Henderson-Hasselbaich equation and corresponds to pKa  value of 3.44 for 27 (data is from 
Dr. Holm Petzold). 
Scheme 5.5 Pathways for the hydrolysis of the sulfenato complex 27. 
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Figure 5.13 	(A) 2D ['H,15N] HSQC NMR spectrum for sulfenato complex 
[(1l6 
hmb)Ru(15N-en)(S(0)-iPr)] (15N-27) containing phosphate buffer (pH
* 7) in 90% D20/10% 
H20 at 310 K. 	(B) 2D ['H,'5N] HSQC NMR spectrum for 16 h after HCI (in 90% 
D20/10% H20) was added to the solution in (A) to change the pH* to 2.11 at 310 K. 
	(C) 
2D ['14, N] HSQC NMR spectrum for [(16-hmb)Ru('5N-efl)Cl] ('5N-28; pH* 2.20) and 
[(1i6 
hmb)Ru(1 N-en)(OH2)I2 (15N-29; pH* 2.20) in 90% D20/10% H20 at 310 K, providing a 
basis for the assignments (Wang, F.; Xu, J.; Habtemariam, A.; Bella, J.; Sadler, P. J. J. Am. 
Chem. Soc. 2005, 127, 17734-17743) in (B). 
5.3.3 Competitive Reaction of 23 or 24 with GSII and cGMP Under 
Physiologically-relevant Conditions 
The reaction of complex 23 (0.1 mM) with 50 mol equiv of GSH and 5 mol equiv of 
cGMP in air (i.e. not purged with Ar) at 310 K for 24 h, was studied by HPLC and 
ESI-MS. The HPLC chromatogram (Figure 5.14) showed that the reaction gave rise to 
three adducts (peaks b, d and e in Figure 5.14), and the three fractions were collected 
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and analysed by ESI-MS. In the mass spectrum of the fraction b (Figure 5.15), a 
singly-charged ion peak centred at m/z 449 was assigned to the sulfenate adduct [(16W 
hmb)Ru(en)(SOPh)} (25), and another singly-charged ion peak centred at m/z 323 to 
a fragment which had lost the SPh ligand from 25. A singly-charged ion peak centred 
at m/z 668 obtained from fraction d is assignable to the monoruthenated cGMP adduct 
[(
11
6-hmb)Ru(en)(cGMP-N7)F (30), and a singly-charged ion peak centred at m/z 646 
and a doubly-charged ion peak centred at m/z 323 from the fraction e are assignable to 
the monoruthenated glutathione sulfenate adduct [( 6-hmb)Ru(en)(S(0)G)] (31). 
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Figure 5.14 	HPLC separation for the reaction of 23 (0.1 mM) with GSH (5 mM) and 
cGMP (0.5 mM) in air at 310 K for 24 h. Peak assignments: (c) sulfenato adduct [(T16 
hmb)Ru(en)(SOPh)} (25); (d) cGMP adduct [(16-hmb)Ru(en)(cGMP-N7)]'(30); (e) 
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Figure 5.15 ESI mass spectra for the HPLC fractions b, d and e (see Figure 5.14) obtained 
from the reaction described in Figure 5.14. 
Due to the broad water signal in NMR spectra for the reaction of 23 with GSH and 
cGMP, the competitive reaction of GSH and cGMP at millimolar concentrations 
(24:GSH:cGMP 2:10:4 mM) was followed by 2D ['H,'5N] HSQC NMR in air (i.e. 
not purged with Ar) at 310 K using '5N-labelled 24 ('5N-24). The spectra are shown in 
Figure 5.16 and 'H and '5N NMR chemical shifts are listed in Table 5.4. During the 
early stages (<2 h), a pair of new cross-peaks (32a1b) was observed for the '5N-en 
ligand in thiolato adduct [(16-hmb)Ru('5N-en)SG} (' 5N-32), which increased in 
concentration until 36 h, and then decreased in concentration until 62 h. After 12 h, 
cross-peaks 27a!b and 27c/d appeared, assignable to the sulfenato adduct [(TI 
6_  
hmb)Ru('5N-en)(S(0)-iPr)f' ('5N-27). After 28 h, another pair of cross-peaks (3laIb 
and 31c) was detectable and can be assigned to the monoruthenated glutathione 
sulfenato adduct [( 6-hmb)Ru('5N-en)(S(0)G)] ('5N-31), and one cross-peak which 
should have same 15  N NMR chemical shift as that of 31 c was covered by the water 
signal. These two sulfenato adducts 27 and 31 increased in concentrations until 62 h. 
All of the assignments were on the basis of the assignments from 2D [1H,15N] HSQC 
151 
NMR time courses for the reactions of '5N-24 (2 mM) with H202 (4 mM) containing 
phosphate buffer (pH 7) and 22 mM NaCl at 310 K (data not shown), and [(16 
hmb)Ru('5N-en)Cl] (' 5N-28; synthesized by Dr. Hoirn Petzold; 5 mM) with GSH (25 
mM) at 310 K (data not show). Another reaction mixture of '5N-27 (2 mM; obtained 
from the reaction of '5N-24 with H202 at molar ratio of 1:1 at 310 K for 1 h) with 
cGMP (4 mM) at 310 K for 24 h in air, was analysed by 2D ['H,'5N] HSQC NMR. 
Two pairs of cross-peaks (30alb and 30c/d) were observed (see Figure 5.17, Table 
5.4), assignable to monoruthenated cGMP adduct [(16-hmb)Ru(
15  N-en)(cGMP-N7)] 
('5N-30) on the basis of the assignment for the ion peak at m/z 670 in the ESI mass 
spectrum for the reaction mixture (data not shown) and the assignment for the 2D 
['H,1 'N] HSQC NMR spectrum of the reaction of 'N-28 (5 mM) with cGMP (50 
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Figure 5.16 2D [1 H,15NI HSQC NMR time course for the reaction of 
15N-24 (2 mM) with 
GSH (10 mM) and cGMP (4 mM) in 90%H20 / 10% D20 containing 50 mM phosphate 
buffer and 22 mM NaCl in air at 310 K over a period of 62 h. Assignments: 24a!b '5N-24 [(TI 
6_ 
 
hmb)Ru('5N-en)(S-iPr)1, 32a1b thiolate adduct ftrj6-hmb)Ru('5N-efl)SGI ('
5N-32), 27a1b and 
27c1d sulfenato adduct 	 ('5
N-27), 31 alb and 31c 
monoruthenated glutathione sulfenato adduct ft
116 hmb)RU(NeflXS(0)G)1 (N-31). 
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Table 5.4 Chemical shifts of 'H,'5N NMR peaks observed for reactions of 15N-24 (2 mlvi) 
with GSH (10 mM) and cGMP (4 mM) in 90%H20 / 10% D20 in air at 310 K (Figure 5.16), 
and N-27 (2 mM) with cGMP (4 mM) in 90%H20 / 10% D20 in air at 310 K for 24 h (see 
Figure 5.17). 
complexes 
	 (peak) ö 'HI 
[(6-hmb)Ru( 
15 N-en)(S-iPr)] ("N-24) (2a) 4.501-2.63 (2b) 3.32/-2.63 
[(i16-hmb)Ru(15  N-en)SG ('N-32) (8a) 4.441-3.73 (8b) 3.64/-3.73 
ftr 6-hmb)Ru(15  N-en)(S(0)-iPr)] 	('5N-27) (5a) 4.55/-6.69 (Sb) 3.587-6.69 
(5c) 4.73/9.75 (Sd) 4.34/9.75 
ftr16-hmb)Ru('5N-en)(S(0)G)] ('5N-31) (7a) 4.501-7.89 (7b) 4.36/-7.89 
(7c) 3.95/7.56 
[(il6 hmb)Ru(l5Nen)(CGMPN7)]+ ('5N-30) (6a) 6.091411 (6b) 4.877-0.11 
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Figure 5.17 2D [H,15N] HSQC NMIR spectrum for the reaction of '5N-27 with cGMP at 310 
K for 24 h. Peak assignments: 27a/b and 27c/d sulfenato adduct {(116-hmb)Ru( 5N-en)(S(0)-







The LC-ESI-MS (Figure 5.14 and 5.15) for the reaction of 23 with GSH and cGMP at 
310 K for 24 h, showed peaks for three products [(i 6 -hmb)Ru(en)(S(0)-iPr)]+  (25), 
[(16-hmb)Ru(en)(S(0)G)] (31) and [( 6-hmb)Ru(en)(cGMP-N7)] (30); whereas the 
2D [1 H,'5N] HSQC NMR time course for the reaction of 15N-24 with GSH and cGMP 
at 310 K for 62 h demonstrated that no cGMP adduct 30 formed after 62 h, which is 
probably due to the presence of TFA in HPLC separation but not involved in NMR 
spectroscopy. Compared to the reaction of 15N-24 bubbled with air continuously in 
presence of GSH at 310 K for 4 h, the reaction of 15N-24 with GSH and cGMP (not 
purged with air continuously) at 310 K for 62 h gave rise to two glutathione adducts, a 
glutathione thiolato adduct [(16-hmb)Ru('N-en)(SG)] ('5N-32) and a glutathione 
sulfenato adduct [(16-hmb)Ru('5N-en)(S(0)G)] ( 5N-31), which is due to the 
deficiency of 02,  leading to the excess of GSH that reacted with 24 to give rise to 32 
(not observed in section 5.3.1.3 due to the existence of sufficient 02), indicating the 
adducts 32 and 31 are side products. On the basis of the studies on the hydrolysis and 
acidity of sulfenato complexes in section 5.3.2, it can be concluded that only in the 
presence of GSH the thiolato complex 24 can be readily oxidized to the sulfenato 
adduct 27, and 27 is relatively stable at pH 7 in the NMR experiment (rate of 
hydrolysis at pH 7 is low); whereas the protonated forms are very unstable sulfenic 
acid complexes [(ij 	(33) and [(16-hmb)Ru(en)(S(OH)G)1 
(34) at pH 2 during HPLC separation. Therefore, the highly reactive sulfenic acid 
complexes 33 and 34 are key intermediates in the competitive reaction of 24 with 
GSH and cGMP. The proposed mechanism is shown in Scheme 5.6. This is the first 
report that Ru(II) arene complexes are oxidized to sulfenates and then protonated to 
sulfenic acid complexes which are active forms instead of aqua complexes as active 
forms shown in Chapters 3 and 4. 
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Scheme 5.6 Proposed pathway for the reaction of 24 with GSI-I and cGMP. The dashed 
pathway represents the side reaction. 
[(ri6-hmb)Ru(en)(S-iPr)J (24)... ._ 	pH 7 







((q6-hmb)Ru(en)(S(OH)-iPr)]2 (33) 	 V 
highly reactive 




Hydrolysis 	 V 







In Chapters 3 and 4, the Ru(II) arene complexes are activated by hydrolysis, however, 
a novel Ru(II) arene complex [(r16-hmb)Ru(en)(SPh)JPF6 (23) shown in this Chapter 
does not hydrolyse, but still shows activity to human ovarian cancer cell A2780 (IC50 
= 23 M). Thus the mechanism of activation was investigated using HPLC, ESI-MS 
and NMR, particularly 2D [H,' 5N] HSQC NMR. 
First the oxidation of complexes 23 and 24 was studied. The thiolato complexes 23 
and 24 can be readily oxidized by air at pH 7 containing 22 mM NaC1 at 310 K only 
in presence of GSH (Figures 5.2, 5.3 and 5.10), and the proposed mechanism is given 
in Scheme 5.3, in which GSH/02 is oxidant. The thiolato complexes 23 and 24 can be 
oxidized to sulfinates by H202 in aqueous solution, which are two-step reactions 
(Figures 5.4, 5.5 and 5.9), and sulfenato adducts are intermediates. 
The competitive reactions of 23 or '5N-24 with GSH and cGMP containing phosphate 
buffer (pH 7) and 22 mM NaCI at 310 K were analysed by HPLC and 2D ['H,15N] 
HSQC NMR. It is proposed that in the presence of GSH, the thiolato complexes are 
oxidized by 02 to sulfenato adducts which protonate slowly at pH 7, forming highly 
reactive sulfenic acid complexes that hydrolyse, and then bind to cGMP to form 
ruthenated cGMP products, as shown in Scheme 5.6. 
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The HPLC fraction b shown in Figure 6.7 was collected and lyophilized for 
NMR studies, and it was found to decompose within hours due to the 
protonation of S. 
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Chapter 6 




When this work began, cisplatin was known to be deactivated by S-donor amino 
acids, peptides and proteins, and not much was known about the competitive 
reactions between N-donor nucleotides and S-donor peptides Ru(II) arene anticancer 
complexes. The expected mono-ruthenated cGMP adduct [(r 6-bip)Ru(en)(cGMP- 
+ 	 6 
N7)] is the major product, rather than glutathione (GSH) adduct [(rj -bip)Ru(en)(SG- 
+ 
8)], from the competitive reaction of [(11 -bip)Ru(en)Cl] with glutathione and 
guanosine-3',5'-cyclic monophosphate (cGMP) at pH 7 at 310 K for 72 h. 
Interestingly, the glutathione adduct was found to be susceptible to oxidation, 
forming the sulfenato adduct [(i16-hip)Ru(en)(S(0)G-S)] which can protonate to form 
the highly reactive sulfenic acid [(ri-hip)Ru(en)(S(OH)G)] , providing a facile route 
for displacement of S-bound glutathione by G N7. Similar results were obtained for 
the reactions of [(ii6-arene)Ru(en)Cl] (arene = bip, tha) with GSH and 14-mer DNA 
oligonucleotides. A dinuclear Ru(0) sulfenate/sulfinate complex {[(r 6-
bip)Ru(0)(GSO2)](.t-S-GSO)2[(GSO2)Ru(0)(r16-bip)] 19- 9  and a tetranuclear complex 
{ {(r 6-bip)Ru(II)(GSO2)]2 [(116 -bip)Ru(l)(GS02)12 8- were observed as products from 
reactions of [( 6-bip)Ru(en)C1] with GSH for the first time, and they probably play 
similar roles to [(i16-bip)Ru(en)(S(0)G-S] in some physiological reactions. 
This thesis has been concerned with the mechanism of cytotoxic action of Ru(II) 
arene complexes with novel leaving groups, e.g. [(11 6 -hmb)Ru(en)(SPh)]
+ 





I6  -hmb)Ru(en)(SPh)] was reported to exhibit anticancer 
activity (1050 = 23 tM, A2780 cells) but cannot hydrolyse to form the active aqua 
species. Surprisingly, GSH/02 is found to be the oxidant in the oxidation of the 
6 	 + 	 6 
Ru(II) thiolate [(Ti -hmh)Ru(en)(S-iPr)] to the sulfenato adduct [(ri - 










6 	 + 
can protonate to form the sulfenic acid complex [(11 -hrnb)Ru(en)(S(OH)-iPr)] 
which readily hydrolyses and binds to cGMP. 
The following part of this Chapter explores future work which could be carried out in 
this project, and some of which is based on preliminary results shown in this thesis. 
6.2 Future Work 
6.2.1 Di- and Tetra- Nuclear Complexes 
6.2.1.1 Confirmation of Structures of Complexes 
In Chapter 3, a dinuclear complex and a tetranuclear complex were analysed by FT-
ICR MS, and the possible structures were given, however, further confirmation is 
needed, such as evidence from infrared (IR) spectroscopy and extended X-ray 
absorption fine structure (EXAFS). It has been reported that the existence of SO, SO2 
and H-bonds (Ru—N—H""OS) can be confirmed by JR spectroscopy. 1 '2 Sulfinato 
complexes show a two-band set, U(SO)asyii and u(SO) 1 in the range of 1030-1190 
cm'; whereas sufenates show u(SO) as single absorbance at ca. 900-920 cm 1 . 11 NH 
stretching from the ethylenediamine ligand coordinated toward the oxygen of SO 
group, has an absorption band range from 3150 to 3400 cm-1.  
[2]  The oxidation states 
of Ru in these two complexes could be confirmed by EXAFS. Therefore, the exact 
structures of these two complexes could be identified. 
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6.2.1.2 Role of Dinuclear Ruthenium Complex 
The dinuclear complex was observed in the reactions both in aqueous solution and 
under physiological conditions (pH 7. 22 mM NaCl) bubbling with Ar, so it is 
supposed to play a role in the physiological reaction. The investigation on the 
competitive reaction of [(TI 	with GSH and cGMP at pH 7 bubbling 
with Ar will be carried out to study the role of the dinuclear ruthenium complex in 
the competition between GSH and cGMP bubbling with Ar, probably it can provide 
a similar facile route for the displacement of S-bound GSH by guanine N7. 
6.2.2 Studies on Ruthenated GST Sulfenate 
6.2.2.1 Determination of Binding Sites 
It was reported that besides cysteine residues, methionine and histidine residues 
(Figure 6.1) are also possible binding sites for ruthenium(II) arene complexes in 
proteins. 13,41  It suggested that the affinity of the (Tj 	fragment for these 
amino acids decreases in the order L-Cys> L-Met> L-HisJ51 The adducts which are 
from the reactions of [(ij 	with L-Met or L-His are [(ij 
[(116-bip)Ru(en)(L-His-N8)J2 	and 	[( 6-bip)Ru(en)(L-His-N)]2 , 
respectively. 3'4'5' There are 9 methionine and 6 histidine residues in the enzyme GST 
used in this thesis as well as 2 reduced cysteine residues, thus determination of 
binding sites for [(ij 	is needed. Recently, the new MS/MS method of 
electron capture dissociation (ECD) 67' for electrosprayed ions cleaves peptide 
backbones primarily at the C - N bond, was used to characterize post-translational 
modifications. 18,91  This new fragmentation method would be applied for determining 













Figure 6.1 Structures of methionine and histidine.1 51 
6.2.2.2 Competition between GST and cGMP 
Hydrogen peroxide (H202), an oxidizing agent known to produce metastable sulfenic 
[1011] 	 6 	 2+ acids, 	would be used to oxidize the thiolato adduct {{(q -bip)Ru(en)12(GST)} 
to the sulfenate. FT-ICR MS can be applied to identify the formation of the sulfenate. 
Then cGMP could be added to the sulfenate solution to investigate the substitution of 
S-bound sulfenate by guanine N7. 
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The reaction of [(ij 	with the enzyme GST and cGMP could be 
investigated at pH 8 at 310 K using HPLC, FT-ICR MS and NMR spectroscopy. A 
similar mechanism will probably be obtained, in which the sulfenate play an 
important role in the displacement of S-bound GST by guanine N7. 
6.2.3 Investigation on the Mechanism Using 17  O NMR 
+ 
In order to confirm the mechanism for the oxidation of [(ii 
6 
-hnih)Ru(en)(S-iPr)] in 
the presence of GSH, '7O NMR spectroscopy would be appliedJ'21 '02 would be 





GSH at pH 7 at 298 K (slowing down the reaction so that good spectra could be 
obtained), and the reaction mixture would be monitored by '7O NMR, and the 'O 
chemical shift for GS'70'70H is in the range of 180-300 ppm; the 'O chemical shift 
for sulfenate is 10-50 ppm)131 Once the mechanism is confirmed, further evidence for 
6 
the possible novel mechanism of cytotoxic action of {(r -hmb)Ru(en)(SR)] (R = 
phenyl, isopropyl) via oxidation would be obtained. 
6.2.4 Ru(II) Anticancer Complexes with Other Arenes 
It was reported that anticancer activity (against A2780) appears to increase with the 
size of the coordinated arene: benzene (bz) <p-cymene (p-cym) <biphenyl (bip) < 
dihydroanthracene (dha) <tetrahydroanthracene (tha),151 and the sequence of rates for 
the reactions of [(i6-arene)Ru(en)Clf with cGMP is consistent with that for 
analogous reactions of ftq6-arene)Ru(en)(OH2 )I12 : tha > bip > dha >> p-cym> bz 
(the structures are shown in Figure 6.2))141  [( 6-tha)Ru(en)C1] was investigated (in 
Chapter 4) in the competitive reaction between GSH and a 14-mer DNA 
oligonucleotide at pH 7 which only gave rise to the monoruthenated DNA adduct. 
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More investigations on competitive reactions of GSH and cGMP/14-mer DNA 
oligonucleotides for [(ij 	(arene = dha, tha, p-cym and bz) can be 
carried out as well as the studies on the mechanisms. Similar results and mechanisms 
to those for [(ij 	could be obtained. 
Arene = 
Arene 7 + <1I >-C--- III 
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Figure 6.2 Ru(II) arene complexes with different arenes. 
6.2.5 0, 0-Chelated Ru(II) Arene Complexes 
For the Ru(JI) arene anticancer complexes containing chelating ligand 
enthylenediamine (en) which is a hydrogen-bond donor, there is exclusive binding to 
guanine nucleobases, and in the absence of guanine there is binding to cytosine or 
thymine, but little binding to adenine basesJ'4"51  It was demonstrated that the 
tropolonato (trop; hydrogen-bond acceptor) complex [(11 	reacted 
with guanosine (Guo) to form N7 adducts (Figure 6.3(A)) and with adenosine (Ado) 
to form both N7 and Ni adducts (Figure 6.3(B) and (C)), and competitive reactions 
with guanosine and adenosine gave rise to guanosine:adenosine adducts in a Ca. 1.3:1 
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mol 	ratio. 1161  It was also reported that for the anionic acetylacetonate (acac; 
hydrogen-bond acceptor) complex [( 6-p-cym)Ru(acac)Cl] (Figure 6.4), the overall 
affinity for adenosine can be greater than for guanosine, and there is little binding to 
cytidine or thymidine.U71  However, no studies on the competition between S-donor 
amino acids (like cysteine, methionine) or peptides (like GSH) or proteins (like 
albumin) and N-donor nucleotides (like guanine and adenine) for these 0, 0-chelated 
Ru(II) arene complexes were explored. Similar investigations on these 0, 0-chelated 
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Figure 6.4 Structures of guanosine and adenosine adducts of ftq6-p-cym)Ru(acac)C J71 
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